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1. SUMMARY 
 
Introduction 
Glucagon-like peptide analogues are a new class of drugs that mimic the hormone glucagon-like 
peptide (GLP-1).  GLP-1 is an incretin, a gastrointestinal hormone that is released into the circulation 
after meals. GLP-1 regulates glucose levels by stimulating insulin production and secretion, and by 
suppressing glucagon secretion, gastric emptying and appetite. 
Circulating GLP-1 undergoes destruction by an enzyme, dipeptidyl peptidase IV (DPP-IV), resulting 
in a half-life of 1 to 2 minutes. The natural form is therefore not suitable as a treatment. 
Some current glucose lowering treatments cause low blood glucose (hypoglycaemia) because they act 
no matter what level the blood glucose is. In contrast, the action of the GLP-1 analogues is glucose 
dependent, that is, the higher the plasma glucose level, the greater the effect of GLP-1 on insulin 
secretion with the greatest effect in hyperglycaemic conditions, and little or no effect when the blood 
glucose concentration is less than 3.6 mmol/l. Hence they do not themselves cause hypoglycaemia. 
There are at present two GLP-1 analogues licensed for use in the UK, exenatide and liraglutide. There 
are also two DPP-IV inhibitors, sitagliptin and vildagliptin, also known as the gliptins. 
 
1.1 Scope of the submission.  
The industry submission from Novo Nordisk addressed the use of liraglutide as a second and third 
drug treatment in people with type 2 diabetes whose glycaemic control was not satisfactory on 
treatment with metformin with or without a second oral agent.  
 
1.2 Evidence on clinical effectiveness. 
The submitted evidence of clinical effectiveness came mainly from the series of studies known as 
the Liraglutide Effect and Action on Diabetes (LEAD) programme. The most relevant amongst 
these were the studies in which liraglutide was used as part of triple therapy, and compared with 
an active comparator. These were LEAD-5, which compared liraglutide with the long-acting 
insulin, glargine, and LEAD-6 which compared liraglutide with another GLP-1 agonist, 
exenatide.  
 
In three trials liraglutide was used as second drug in dual combination therapy.  LEAD-1 compared it 
with rosiglitazone, both in combination with sulphonylurea.  LEAD-2 compared it with glimepiride, 
both in combination with metformin.  An unpublished trial NN2211-1860 compared liraglutide with a 
DPP-4 inhibitor, sitagliptin. 
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All these trials were sponsored by Novo Nordisk, and company staff were involved in study design, 
data collection, data review and analysis. However, we judged all the trials to be of good quality, and 
the analysis to be fair and unbiased. 
 
The primary outcome was glycated haemoglobin, the standard measure of control of blood glucose. 
Other outcomes included weight gain or loss, blood pressure, fasting plasma glucose, lipids and 
adverse effects.  
 
Triple therapy studies. 
LEAD-5 reported that, 
 liraglutide 1.8 mg daily reduced HbA1c by 0.24% more than glargine 24 units/day.  
 weight was reduced on liraglutide but increased on glargine, giving a weight difference of  
3.4 kg at end of study in favour of liraglutide 
 end of study systolic blood pressure (SBP) difference was 4.5 mmHg in favour of liraglutide. 
 With an end of study daily dose of only 24 units, it may be that glargine was not used to best effect. 
Though had the dose been increased, and HbA1c lowered, it is likely that weight gain would have 
been greater, and the SBP difference also larger.  
 
 In LEAD-6,  
 liraglutide 1.8 mg daily reduced HbA1c by 0.33% more than exenatide 
 Systolic BP and weight showed no significant differences. 
 There was less nausea with liraglutide once daily than with exenatide twice daily. 
 
Dual therapy studies 
In LEAD-1, 
 HbA1c was reduced by 1.08% in the liraglutide 1.2 mg arm and by 1.19% in the liraglutide 
1.8 mg arm, and in the rosiglitazone 4 mg arm by 0.44%.  It rose by 0.23% in the placebo 
arm. 
 Weight was reduced by 0.2 kg and 0.1 kg in the liraglutide 1.8 mg and placebo arms 
respectively. In the liraglutide 1.2 mg and rosiglitazone arms, it increased by 0.3 kg and 2.1 
kg respectively. 
 Systolic BP decreased in the range of 2.6 to 2.8 mmHg in the liraglutide 1.2 and 1.8 mg arms 
while the reduction in the placebo and rosiglitazone arms was between 0.9 to 2.3 mmHg.  
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So compared to rosiglitazone 4 mg, there was a significant difference in HbA1c but no difference in 
weight and SBP. However note that this was with rosiglitazone 4 mg daily.  Rosiglitazone is often 
used in a dose of 8 mg daily. 
 
In LEAD-2, 
 HbA1c was reduced by 1% in the liraglutide 1.2 and 1.8 mg arms, and in the glimepride 
group. It rose by 0.1% in the placebo group 
 Weight was reduced by 2.6 and 2.8 kg in the liraglutide 1.2 and 1.8 mg groups, and by 1.5 kg 
in the placebo group, giving placebo-adjusted losses with liraglutide of 1.1 and 1.3 kg. 
Weight rose by 1 kg with glimepiride. 
 Systolic BP fell by 2.8 mmHg in the 1.2 mg liraglutide arm, by 2.3 mmHg in the 1.8 mg arm, 
and by 1.8 mmHg in the placebo arm. It rose by 0.4 mmHg in the sulphonylurea arm. Hence 
the placebo-adjusted SBP reductions with liraglutide were 1 and 0.5 mmHg. 
So compared to glimepiride, there was no difference in HbA1c but liraglutide provided a weight 
advantage of 3.7 kg, and SBP difference of  3.2 mmHg. 
 
In the unpublished trial, compared to sitagliptin, 
 ******************************************************* 
 ******************************* 
 *******************************. 
 
In summary, liraglutide is a clinically effective drug which improves glycaemic control, but also 
provides benefits in weight and blood pressure. 
 
1.3 Evidence on cost-effectiveness. 
The industry submission used the CORE economic model of diabetes, a highly-developed and well-
respected model. The CORE model is not standard software as defined by NICE, but the manufacturer 
confirmed with NICE that its use would be acceptable. 
The manufacturer presented three main sets of analyses, based upon the three main clinical trials 
noted above: 
 LEAD-5 comparing liraglutide 1.8 mg with glargine 
 LEAD-6 comparing liraglutide 1.8 mg with exenatide 
 1860 comparing liraglutide 1.2 mg and 1.8 mg with sitagliptin 
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Initial treatments were assumed to be for 5 years in the base case, with patients then switching to 
glargine. 
 
The ERG has checked parameter values in the submission against published literature, and also 
checked the values against those within the CORE model. Only some minor discrepancies of no 
significance were found. 
 
The ERG re-ran the base cases within CORE. Results matched those reported by the manufacturer 
within the submission.  
 
For the base cases the manufacturer estimated a cost effectiveness of: 
 £15,130 per QALY for liraglutide 1.8 mg compared to glargine 
 £10,054 per QALY for  liraglutide 1.8 mg compared to exenatide 
 £10,465 per QALY for  liraglutide 1.8 mg compared to sitagliptin 
 £9,851 per QALY for  liraglutide 1.2 mg compared to sitagliptin 
 
Additional sub-group analyses undertaken by the manufacturer suggested that for patients of a higher 
BMI liraglutide was typically more cost effective. The estimates of cost effectiveness for those of a 
lower BMI were not presented. 
 
Univariate sensitivity analyses undertaken by the manufacturer suggested that these estimates were 
most sensitive to: 
 the assumed duration of initial therapy 
 the application of weight changes and disutility associated with this 
 the time horizon of the analysis 
 
Additional sensitivity analyses undertaken by the ERG suggested that the main sources of the 
estimated patient benefits were: 
 the direct utility effects of BMI changes and SBP, with some additional contribution from 
HbA1c, for the comparison with glargine 
 HbA1c, with some additional effects from cholesterol and triglycerides, for the comparison 
with exenatide 
 HbA1c and direct utility effects of BMI changes for the comparison with sitagliptin 
Overall, the ERG regards the industry analysis as a fair representation of the cost-effectiveness. 
 
1.4 Robustness of submitted evidence. 
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1.4.1 Strengths and weaknesses of evidence. 
Novo Nordisk has carried out a large number of trials, but in the submission has focused on the LEAD 
studies. The quality of trials appears good. These are reasonably large studies carried out in a large 
number of centres in many countries, increasing the generalisability of the results. However few 
patients came from the UK, and the ethnic mix of some trials reflects the US centres. 
 
Some of the trials included in the submission were not relevant to UK practice as recommended in the 
NICE Guideline CG87, where the GLP-1 analogue (at that time, only exenatide) was recommended 
only for third line use (i.e. being added to two oral agents) despite being licensed also for second-line 
use.  Liraglutide has also been approved by EMEA for second-line use (in combination with one oral 
agent). The recommendations of CG87 are reported in the industry submission. 
 
In LEAD-4, the comparator drug was rosiglitazone. It could be argued that pioglitazone would have 
been a better choice, since it has a more favourable risk profile than rosiglitazone. Both cause heart 
failure and fractures, but rosiglitazone appears to slightly increase cardiovascular mortality whereas 
pioglitazone reduces it. In a recent UK study, rosiglitazone was associated with a 34% to 41% higher 
risk of all cause mortality compared to pioglitazone.  Some regulatory bodies have now placed 
warnings on rosiglitazone use.  
 
Because the trials were short-term, it was necessary to model costs and outcomes far beyond the 
duration of the trials. The duration of the direct benefits from initial treatments may have been too 
long, and the direct disutility associated with these changes may also have been too large. 
 
In line with the NICE policy of only considering licensed products, we compared liraglutide with 
existing comparators, using a 40 year duration. In reality, daily liraglutide will soon be displaced by 
other GLP-1 agonists which are given weekly or fortnightly. 
 
1.4.2 Areas of uncertainty 
Most of the trials were of short duration, whereas type 2 diabetes is a long-term condition. Given the 
progressive nature of the disease, and the fact that the GLP-1 agonists depend on functioning beta 
cells, we do not know how long their effect would last. The industry modelling used a baseline 
duration of five years, which is reasonable pending longer term results. It is possible that the GLP-1 
agonists may prolong beta-cell function, but that is not proven in humans at present. 
 
1.5 Key issues 
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There is a good evidence base for the clinical effectiveness of liraglutide.  It helps improve diabetes 
control, and has the additional benefits of some weight loss in most users.  
 
Liraglutide appears safe but that can only be confirmed once there are long term data. 
 
There are some uncertainties about the cost-effectiveness because of the need for long-term modelling 
based on data from short-term trials. An important issue is that some current comparisons, for 
example between the two available GLP-1 analogues, daily liraglutide and twice daily exenatide, will 
be rendered obsolete shortly, with the arrival of longer-acting GLP-1 analogues given once a week or 
perhaps once every two weeks. 
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2. BACKGROUND 
2.1 Manufacturer’s description of underlying health problem. 
Section 4.1 of the industry submission gives a brief but accurate description of type 2 diabetes, and of 
the current treatments and the order in which they are usually used. It also correctly notes that existing 
treatments are not entirely satisfactory because of the adverse effects, notably hypoglycaemia and 
weight gain, and because none affects the underlying disease progression. 
 
One form of treatment not mentioned is intensive lifestyle intervention as an alternative to 
commencing insulin in people poorly controlled on combination oral therapy, but the evidence base 
for this is currently sparse, consisting of one small trial by Aas and colleagues.
1
 That trial randomised 
people failing on oral agents to either start insulin, or to have an intensive lifestyle intervention (diet 
and exercise). The lifestyle group did better. However until these results need to be replicated in a 
much bigger trial with longer follow-up.  
 
2.2 Manufacturer’s overview of current service provision 
 
The Novo Nordisk submission summarises the recommendations of NICE Clinical Guideline 87 and 
hence correctly sets the context for the use of liraglutide as third line drug. However it also advocates, 
in line with the licensed indications, that liraglutide could also be used as the second-line drug in 
addition to metformin or a sulphonylurea, which is not in line with the NICE guideline 
recommendations.  However it identifies particular situations where this might be considered (section 
4.4) including cases where further weight gain would be particularly undesirable, or where weight 
loss would be particularly desirable, for example in people with obstructive sleep apnoea. 
One situation where the submission envisages use, is when self-monitoring of blood glucose (SMBG) 
is difficult or not possible, but since the value of SMBG in people with type 2 diabetes, not on insulin, 
is unproven, this is not convincing as an indication for using liraglutide second-line. 
 
The submission notes that many patients fail to reach the NICE target for HbA1c of 6.5%, but does 
not discuss the recent debate on whether that target is the correct one. Much debate has followed the 
early termination of the ACCORD study, after the intensive glycaemic control group (target HbA1c 
<6.0%) was found to have an increased risk of death compared with the group aiming at HbA1c of 7 
to 7.9%.
2
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In LEAD-5, liraglutide 1.8 mg was compared with glargine. The NICE clinical guideline CG 87
3
 
recommended NPH as the first choice basal insulin in type 2 diabetes, because the marginal benefits 
are small and the marginal cost considerable. 
4
 So it could be argued that glargine was the wrong 
comparator. One might also wonder why Novo Nordisk used glargine as the comparator rather than 
their own basal analogue insulin, detemir. However, the report, Prescribing for Diabetes in England
5
 
shows that glargine is now by far the most commonly used long-acting insulin, with NPH in steady 
decline. There are about three times as many prescriptions for glargine as for NPH, which has also 
recently been overtaken by detemir. So it could be argued that on pragmatic grounds, using glargine 
as the comparator was simply recognising prescribing reality. 
 
One problem in type 2 diabetes is addressed only briefy in the industry submission (page 10). This is 
that type 2 diabetes is usually a progressive disease, requiring intensification of treatment over time. 
So patients will start on diet and lifestyle measures alone, but over time will require additional 
treatment with drugs, usually with metformin monotherapy, followed by the addition of a 
sulphonylurea, and in due course a third drug, which may be another oral agent , or insulin. The flow 
diagram below (Figure 1) from the NICE clinical guideline on the management of type 2 diabetes 
illustrates this.
3
 
 
Figure 1 Care pathway for diabetes drugs  
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The need to intensify treatment arises because the functioning of the insulin-producing beta cells in 
the pancreas declines over time. This was shown in the UK Prospective Diabetes Study (UKPDS 16)
6
 
and was seen irrespective of treatment group (metformin, sulphonylurea or insulin).  More recently, it 
has been asserted that the time to failure of monotherapy may be longer with metformin and 
rosiglitazone than with the sulphonylurea, glibenclamide (ADOPT study
7
) though at the cost of 
greater weight gain (rosiglitazone  vs metformin 6.9 kg greater at four years; rosiglitazone vs 
glibenclamide 2.5 kg greater). 
 
Current practice in the UK when patients are not achieving good control on combination oral drugs, is 
to start insulin. However another problem, not covered in the submission, is that many people with 
type 2 diabetes remain poorly controlled on combinations of oral agents for quite long periods before 
starting insulin.  Two studies from the UK have used general practice databases to examine glycaemic 
control and treatment. 
 
Calvert and colleagues used data from the DIN-LINK database of anonymised data from 154 general 
practices, from the years 1995 to 2005, on patients with type 2 diabetes, including the treatment they 
were on and their HbA1c levels.
8
 They were particularly interested in how long patients remained 
poorly controlled on oral agents before starting insulin. They identified all patients with type 2 who 
were prescribed two or more types of oral agent, and looked at their HbA1c levels before and after the 
addition of another drug.  The median time from addition of the last oral agent to the start of insulin 
therapy, for patients on two or more oral agents, was seven years. In those with poor glycaemic 
control following addition of the last oral drug, only 27% were prescribed insulin during the study. 
The implication is that many patients were left poorly controlled rather than being switched to insulin. 
Rubino and colleagues used another British GP database, The Health Improvement Network (THIN) 
database, to identify patients with type 2 diabetes who were poorly controlled (at two levels, >8% and 
>9%) on oral agents, and who had not been treated with insulin. They then followed them to see how 
long it was before insulin was started.
9
 
Using the cut-off for poor control of HbA1c of 8% or over, they found 2501 eligible patients, mostly 
aged 50-79 years, and with duration of diabetes usually at least five years. Most had been on oral 
glucose lowering agents (OGLAs) for over five years. About 25% of these patients started insulin by 
two years, and 50% by 5 years. So transition was slow, and many were not transferred to insulin at all. 
When OGLA failure was defined as HbA1c of 9% or over, they found 1691 patients who qualified. 
By 4.2 years, 50% had started insulin.  
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Why is there reluctance to use insulin? 
 
In a previous technology assessment report for NICE, on inhaled insulins, we pondered upon why 
there should be reluctance.
10
 There seemed to be reluctance amongst both patients and physicians.  
 
The DAWN (Diabetes Attitude Wishes and Need) study found that 55% of patients who have never 
had insulin treatment are anxious about it being required.
11
 The authors, Peyrot and colleagues, 
reviewed previous studies of patient attitudes to insulin therapy.  They noted  that these involve 
beliefs that;
11
 
 
“taking insulin: 
 Leads to poor outcomes including hypoglycaemia, weight gain and complications 
 Means that the patient’s diabetes is worse and that the patient has failed 
 Means life will be more restricted and people will treat the patient differently 
 Will not make diabetes easier to manage.” 
 
It is important to note that insulin treatment is not just about injections, but a whole package of care 
including dietary adjustments, home blood glucose testing, and self-adjustment of insulin doses. It is 
likely that for most people, insulin injections are less troublesome than blood testing.  
 
Changing to insulin does not mean that control will improve. Unpublished data from the Lothian audit 
show that the average HbA1c in type 2 diabetes mellitus patients on insulin is about 8.5%. (J 
McKnight, personal communication, presented at RCPE conference, September 2005). The average 
for those with type 2 diabetes mellitus on OGLAs is 7.5%. 
 
The study by Calvert and colleagues noted that control improved after insulin was started, but that 
many patients did not achieve targets.
8
  
 
Similarly, a study from seven European countries found that only 9.5% of patients with T2DM who 
were on insulin, had HbA1c <6.5%; another 44% had HbA1c levels of 6.5% to 7.5%; and 47% had 
levels over 7.6%.
12
 
 
Hayward and colleagues noted that results from trials of insulin therapy in type 2 showed it to be 
efficacious, but thought that these results might not be replicated in routine care.
13
 In a very large 
study (8668 patients with type 2 diabetes) they found that “insulin therapy was rarely effective in 
achieving tight glycemic control”. Two years after starting insulin therapy, 60% still had HbA1c 
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levels of 8% of greater; 25% had levels between 8.0 and 8.9%; 20% between 9.0 and 9.9%; and 15% 
had levels over 10%.  These are similar to the population-based audit from Lothian. 
 
That starting insulin in routine care usually fails to give good control in people with T2 DM failing on 
oral agents, is presumably one reason why the physicians in the DAWN study showed considerable 
resistance to starting insulin therapy in T2DM – only about half of the physicians thought that insulin 
would be useful. 
11
 
 
Yki-Jarvinen and colleagues came to similar conclusions in people with T2DM who were obese 
(defined in this study as BMI over 28.1 kg/m
2
) – insulin did not improve control.   In many of these 
patients, poor control is associated with overweight or obesity.
14
  
 
To some extent, the poor results with insulin may reflect poor compliance. Donnelly and colleagues 
from Tayside found that some people with type 2 diabetes treated with insulin did not take all the 
insulin they were prescribed, and that poor compliance was associated with poor control.
15
 
 
To summarise these aspects of the background; 
 Type 2 diabetes is a progressive disease requiring intensification of treatment over time 
 The UK experience is that many patients are left poorly controlled for years on combinations 
of oral agents, before insulin is started, presumably because of the perceived disadvantages of 
insulin treatment  
 Many patients do not achieve good control even after insulin is started, partly because of 
weight gain. 
Hence there is a need for better treatments for type 2 diabetes. 
Liraglutide is the second of the glucagon-like peptide analogues to be considered by NICE. The first 
was exenatide, which was considered in the updated clinical guideline on management of type 2 
diabetes.  
 
Other GLP-1 agonists are coming, most of which are given weekly or perhaps fortnightly. They 
include exenatide LAR, albiglutide and taspoglutide. 
 
2.3 Manufacturer’s definition of decision problem 
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The Novo Nordisk definition of the decision problem is similar to the scope as decided by NICE. It is 
worth noting that the NICE scope differs from the NICE clinical guidelines, by including the use of 
the GLP-1 agonist as second drug after metformin or a sulphonylurea. This is in line with the licensed 
indications for liraglutide. The NICE guideline makes no recommendation on use of GLP-1 agonists 
as second drugs.  
 
In brief, 
 
 The population is people with type 2 diabetes 
 The intervention is liraglutide, either 1.2 mg or 1.8 mg daily 
 The main comparators are glargine and exenatide as third drugs, and sitagliptin, rosiglitazone  
and glimepiride as second drugs. This is similar to the NICE scope, but that also included 
metformin. However metformin is the usual first line drug in type 2 diabetes, and so is not 
actually a correct comparator. 
 The outcomes are glycaemic control as reflected in HbA1c, weight change, blood pressure, 
fasting plasma glucose and lipids. The NICE scope included complications of diabetes but 
those could only be detected in trials longer term that is feasible in this situation. The 
manufacturer therefore adopts the usual practice of using the short-term outcomes in a 
modelling exercise to estimate long-term complications. 
 The economic analysis adheres closely to the NICE reference case (see comparison in our 
economic section) but omits personal social services (PSS) costs, on reasonable grounds 
 Subgroup analysis includes two groups specified in the final scope, weight and baseline 
HbA1c, but not the third, cardiovascular risk, in which data are lacking. 
 
2.4 The costs of diabetes drugs 
 
Figure 2 below shows some costs of commonly used diabetes drugs, based, except for Liraglutide,  on 
costs in the BNF 58, September 2009.
16
  Note that these are for illustration and equipotency is not 
implied. 
 
 
Copyright 2010 Queen's Printer and Controller of HMSO. All rights reserved.
22 
 
 
Figure 2 Comparative costs of one year of therapy (based on BNF 58 September 2009 except for 
liraglutide) 
 
 
 
 
 
£0 £200 £400 £600 £800 £1,000 £1,200 £1,400 £1,600
Gliclazide 80 mg/day 
Metformin 1 gm/day 
Metformin 2 gm/day  
Glimepiride 1mg/day
Gliclazide 320 mg/day 
Glimepiride 4mg/day
Pioglitazone 15 mg/day 
NPH 50 IU day
Biphasic human insulin 50 IU/day
Rosiglitazone 4 mg/day
Biphasic Insulin Aspart 50 IU day
Biphasic Insulin Lispro 50 IU/day
Rosiglitazone 8 mg/day
Vildagliptin 100 mg/day
Glargine 50 IU/day
Pioglitazone 45mg/day 
Detemir 60 IU/day
Exenatide 20 mcg/day
Liraglutide 1.2 mg/day
Liraglutide 1.8 mg/day
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3. EVIDENCE ON CLINICAL EFFECTIVENESS 
 
The manufacturer’s submission listed a large number of trials, but most were not relevant to the 
decision problem, and the manufacturer focused on those which were most relevant.  For 
completeness, in Appendix 1 we include the table of all the trials identified by the manufacturer in the 
industry submission, and have added our reasons for excluding some from our Cochrane review on 
GLP-1 analogues for type to diabetes (in preparation).   
 
We considered the manufacturer’s submission to be of good quality. All relevant trials were included. 
We cross-checked against our own searches for the Cochrane review. 
 
We identified a number of discrepancies between different parts of the submission, and between the 
submission and published papers, but these were mostly minor, and arose because of rounding in 
some papers but not others, or because some figures came from different analyses such as intention to 
treat, or as observed, or adjusted.  
 
We used the submission, the published papers, and the full clinical trial reports for LEAD-5 and 
LEAD-6, and 1860, which were provided by Novo Nordisk.  One author attended a satellite 
symposium at the 20
th
 World Diabetes Congress in Montreal in October 2009, where the LEAD 
studies were presented and discussed, and there were also presentations and posters at the main WDC. 
 
In line with the NICE guideline on type 2 diabetes (CG 87) we start by considering use of liraglutide 
as third drug, and then as second. 
 
3.1  Liraglutide as third drug 
Based on the NICE guideline (CG 87) on the management of type 2 diabetes, the main indication for 
GLP-1 agonists would be as the third drug in people whose control is unsatisfactory on a combination 
of two oral agents, usually metformin and a sulphonylurea. Some patients would be unable to tolerate 
these and might be taking a glitazone or a gliptin instead. The recommendation from the guideline is 
in Box 1. 
 
Box 1: NICE recommendations on use of exenatide. 
GLP-1 mimetic (exenatide) 
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Consider adding a GLP-1 mimetic (exenatide) as third-line therapy to first-line metformin and 
a second-line sulfonylurea when control of blood glucose remains or becomes inadequate 
(HbA1c ≥ 7.5%, or other higher level agreed with the individual), and the person has: 
 a body mass index (BMI) ≥ 35.0 kg/m2 in those of European descent (with 
appropriate adjustment for other ethnic groups) and specific psychological or medical 
problems associated with high body weight, or 
 a BMI < 35.0 kg/m2, and therapy with insulin would have significant occupational 
implications or weight loss would benefit other significant obesity-related 
comorbidities.  
Only continue GLP-1 mimetic (exenatide) therapy if the person has had a beneficial 
metabolic response (a reduction of at least 1.0 percentage point in HbA1c and a weight loss of 
at least 3% of initial body weight at 6 months).  
 
The trials relevant to the use of liraglutide as third drug are LEAD-4 (Zinman 2009)
17
,  LEAD-5 
(Russell-Jones 2008)
18
 and LEAD-6 (Buse 2009).
19
 The last is included because the majority of 
patients were on triple therapy – 63% on metformin and a sulphonylurea.  
 
Figure 3 gives an overview of the LEAD trials.
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Figure 3 The Liraglutide Effect and Action on Diabetes (LEAD) programme Overview 
 
 
Garber et al. 2009 
glimepiride 
Nauck et al. 2009 
glimepiride 
Marre et al. 2009 
rosiglitazone 
Russell-Jones et al. 
2009 
63% met+SU, 27.5% met only, 10% SU 
only 
Buse et al. 2009 
rosiglitazone 
Zinman et al. 2009 
glimepiride 
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The ones which are most relevant to triple therapy are LEAD-5, in which liraglutide was compared 
with the long-acting analogue insulin, glargine, and LEAD-6 where liraglutide was compared with 
exenatide.  
 
It should be noted that the evidence is that in most patients with type 2 diabetes, glargine is not cost-
effective compared to NPH insulin as a single daily basal injection, and that NPH was recommended 
in the NICE guideline.
4
The cost of NPH is under half that of glargine.  None of the LEAD studies 
compared liraglutide with NPH insulin. 
 
LEAD-5 had three arms but one is not relevant for comparing the options for triple therapy.  The trial 
compared: 
 
Liraglutide 1.8 mg + metformin + glimepiride 
versus 
glargine + metformin + glimepride 
versus 
metformin + glimepiride 
 
Our review assessed the quality of this trial as good as shown in Table 1  
 
Table 1 Risk of bias table for LEAD-5 
Item Judgement Description 
Adequate sequence generation? Yes Randomised as 2:1:1 using a 
telephone or web-based 
randomisation system 
Allocation concealment? Yes Central randomisation using a 
telephone or web-based 
randomisation system 
Blinding? Partial Investigators, participants, and 
study monitors were blinded to 
liraglutide, open label glargine 
Incomplete outcome data 
addressed? 
Yes Missing data were imputed as 
the last observation carried 
forward (LOCF), ITT analysis, 
adequate description of 
withdrawals and losses to 
follow-up 
Free of selective reporting? Yes Included all pre specified 
outcomes 
Groups comparable at baseline? Yes  
Sample size calculation? Yes Study was powered to 
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determine a 3% difference in 
weight with a combined power 
>85% 
 
So the trial appears to be of good quality, since it was impractical to blind the glargine arm. 
The dose of liraglutide was fixed.  According to the main paper, the dosage of glargine was titrated by 
a patient driven algorithm based on fasting plasma glucose (FPG).  Patients were asked to adjust the 
dose twice weekly in the first 8 weeks, based on self-measurement of FPG, aiming for a value of 5.5 
mmol/l or less. After 8 weeks, investigators could do as they thought best, but were expected to adjust 
the glargine dose at the 12 and 18 week visits. At the end of the study, the average dose of glargine 
was 24 units a day. 
 
One question is whether glargine was used to best effect – should the dose have been higher?  
 
The end of study dose of glargine was 0.28 units/kg/day.  This seems quite a low dose for patients 
with poor control who had been started on insulin 6 months earlier.  A starting dose of 0.2 
units/kg/day would seem reasonable but with active titration one might have expected the end of study 
dose to have been high – say 0.4 units/kg/day 
 
The main results are summarised in Table 2 .  NB In these tables, we give the observed baseline 
and final data, but the differences or changes are taken from the ANCOVA model ITT analysis 
set, and may not always be the same as a simple subtraction would give. 
 
 Table 2 Main results from LEAD-5. 
 Liraglutide arm Glargine arm 
HbA1C   
  Baseline 8.3% (SD 0.9) 8.2% (SD 0.9) 
  End of study 7.0% (SD 1.0) 7.2 (SD 0.9) 
 Change from baseline -1.33% (SE 0.09) -1.09 (SE0.90) 
                      Difference -0.24% (-0.08 to -0.39; P = 0.0015) in favour of liraglutide 
% reaching HbA1c <7.0% 53.1% 45.8% 
FPG   
 Baseline 9.1 mmol/l (SD 2.1) 9.1 (SD 2.0) 
End of study 7.7 mmol/l(SD 2.2) 7.4 (SD 2.1) 
Change from baseline -1.55 mmol/l -1.79 mmol/l 
NS difference -0.24 mmol/l (-0.31 to 0.60);  P= 0.2002 in favour of glargine  
Weight   
Baseline   85.8 kg (SD 19.3) 85.2 (SD 17.9) 
End of study 84.8 kg (SD 19.1) 86.9 kg (SD 18.1) 
Change -1.81 kg (SE 0.33) + 1.62 kg (SE 0.33) 
                                    Difference 3.43 kg (-4.00 to -2.86); p<0.0001 in favour of liraglutide 
SBP   
Baseline 134.9  mmHg (SD 14.9) 133.0 mmHg (SD 14.7) 
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End of study 132.0 mmHg (SD 14.7) 134.6 mmHg (SD 16.3) 
Change from baseline -3.97 mmHg (SE 1.31) +0.54 mmHg (SE 1.33) 
Difference -4.51 mmHg (-6.82 to -2.20); p=0.0001 in favour of liraglutide 
 
Glargine dosage in other trials  
 
In the Bunck and colleagues RCT of glargine vs exenatide, the final glargine dose was 34 units/day 
and the reduction in FPG was greater with glargine.
20
  However this study is not strictly comparable 
with LEAD-5 because recruits in the Bunck trial were on only metformin monotherapy.  
 
Similarly the Barnett and colleagues RCT of exenatide versus glargine was in patients on 
monotherapy.
21
  In that study, FPG fell more with glargine than exenatide, which is what one would 
expect given that the GLP-1 analogues target postprandial more than fasting glucose whereas basal 
insulin does the reverse.  The dose of glargine was about 27 units/day. 
 
In the Heine and colleagues trial of exenatide vs glargine the reduction in FPG was greater in the 
glargine group – 1.4 mmol/l and 2.9 mmol/l respectively, with 22% of the glargine group and 9% of 
the exenatide group achieving FPG under 5.6mmol/l.
22
 The dose of glargine in that study was 25u/d, 
similar to that in LEAD-5. 
 
In other trials of glargine, end of study doses were 32 units/day in the Pan and colleagues study
23
 
(versus NPH, both in combination with glimepiride, with a reduction in HbA1c of 0.99% from 
baseline 9%) and 33 units/day in the study by Wang and colleagues
24
 (also against NPH, both in 
combination with glipizide, with a drop in HbA1c of 1.15% from baseline 8.8%).  In both those trials, 
the titration target was 6.7 mmol/l or less. 
 
The investigators note that doses of glargine have been higher in studies with more frequent contact 
schedules, but argue that the results in LEAD-5 are similar to other trials in which titration is driven 
by patients, such as in the study by Heine and colleagues, mentioned above, which had an end of 
study glargine dose of 24 units.  However they note that other trials have had higher end of study 
glargine dose.
25,26
 In the HEELA trial of exenatide versus glargine, the mean final dose of glargine 
was 39 units/day.
26
  
 
So there may be some doubt as to whether better results could have been obtained with glargine, 
though the investigators could argue that the results reflect the sort of patient-led titration likely to be 
seen in routine care, away from the more intense contact of some trials. 
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The industry submission does not discuss whether the dose of glargine as used in the LEAD-5 trial 
was sufficient, but in the modelling a dosage of 40 units per day is used after year 1. The cost of 
titration is mentioned but without a cost being included (page 62). 
 
Note that despite the dosage of glargine being increased after year 1, no difference appears to be made 
in HbA1c.  So the industry modelling increases the dose, and hence the cost, without including a 
reduction in HbA1c.     
 
Summary of LEAD-5 liraglutide versus glargine as third drug 
Liraglutide 1.8 mg daily reduced HbA1c by 0.24% more than glargine 24 units/day.  The end of study 
weight and SBP differences were 3.4 kg and 4.5 mm/Hg in favour of liraglutide.  It may be that 
glargine was not used to best effect, but had the dose been increased, and HbA1c lowered, it is likely 
that weight gain would have been greater, and the SBP difference also larger.  
 
LEAD-6 
LEAD-6 was also a good quality trial as shown in Table 3. 
 
Table 3 Risk of bias table for LEAD-6 
Item Judgement Description 
Adequate sequence generation? Unclear 
Randomly assigned (1:1) to the 
lowest available number of the 
numbers allocated to the site 
Allocation concealment? Yes Telephone or web based 
randomisation 
Blinding? No Open label 
Incomplete outcome data 
addressed? 
Yes Last observation carried 
forward data with repeated 
measures analysis and multiple 
imputation methods, ITT 
analysis, adequate description 
of withdrawals and losses to 
follow-up 
Free of selective reporting? Yes All pre specified outcomes 
reported 
Groups comparable at baseline? Yes  
Sample size calculation? Yes 85% power to detect an HbA1c 
difference of 0.4% betweeen 
groups 
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The main results of LEAD-6 are shown in  
Table 4 
 
Table 4 Main results of LEAD-6. 
 Liraglutide arm (1.8mg) Exenatide arm 
HbA1C   
  Baseline 8.2% (SD1.0 ) 8.1% (SD 1.0) 
  End of study 7.0% (SD 0.87 )  7.2% (SD 0.99)  
 Change from baseline - 1.12% (SE 0.08) - 0.79% (SE 0.08) 
                                    Difference – 0.33% (-0.47 to -0.18); p<0.0001 in favour of liraglutide 
% reaching HbA1c <7.0% 54 43 
FPG   
 Baseline 9.8 mmol/L (SD 2.5) 9.5 mmol/L (SD 2.4) 
End of study  7.7 mmol/L (SD 1.9)  8.6 mmol/L (SD2.1) 
Change from baseline - 1.61 mmol/l (SE 0.20) -0.60 mmol/l (SE 0.20) 
                                 Difference – 1.01 (-1.37 to -0.65); p<0.0001 in favour of liraglutide 
Weight   
Baseline   93.1 kg (SD 20.1) 93.0 kg (SD 19.5) 
End of study 91.1 kg (SD 20.3) 91.1 kg (SD 17.8) 
Change from baseline - 3.24 kg (SE 0.33) - 2.84 kg (SE 0.33) 
                                    NS difference   -0.38 kg (-0.99 to 0.23); P=0.2235  in favour of Liraglutide 
SBP   
Baseline  132.0 mmHg (SD 16.2) 134.4 (SD 17.0) 
End of study 129.7 mmHg (SD 16.2) 131.7 mmHg (SD 15.5) 
Change from baseline - 2.51 mmHg (SE 1.15) -2.00 mmHg (SE 1.18) 
NS difference -0.51 mmHg (-2.66 to 1.64); p =0.6409 in favour of liraglutide  
 
The main adverse effect was nausea, and this was reported to be less with liraglutide than with 
exenatide. Initial frequencies were similar, but nausea was reported to be mild and transient with 
liraglutide, and no disutility was included in the modelling. We think this is reasonable. Full details 
and discussion on nausea are in Appendix 2. 
 
In summary, in LEAD-6, liraglutide 1.8 mg daily reduced HbA1c by 0.33% more than exenatide.  
Systolic BP and weight showed no significant differences. There was less nausea with liraglutide once 
daily than with exenatide twice daily. 
 
Trials of third-line liraglutide against placebo 
The part of LEAD-5 described above addressed the question of whether liraglutide or glargine was 
better as the third line drug. The next two comparisons, from LEAD-5 and LEAD-4, used placebo 
control instead of an active comparator. They can be regarded as addressing a clinically useful 
question: in patients with unsatisfactory control on two oral agents, is the addition of liraglutide 
sufficient to achieve good control? However for cost-effectiveness analysis when there is a choice of 
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agents, the key question is which agent is best, and so these trials are not helpful for economic 
analysis. 
 
The placebo arms serve two purposes. Firstly, they tell us how much of the improvement seen might 
be due to just being in a trial, with regular follow-up, probably more often than in usual practice, and 
protocol driven data collection which itself may improve results. Secondly, in longer trials the placebo 
arm might provide data on natural history and progression of disease (so that if the active arm showed 
no change, that could be regarded as a benefit). 
 
LEAD-5  included a placebo arm with the following comparison; 
 
Liraglutide 1.8mg + metformin + glimepiride  
versus  
placebo + metformin + glimepiride 
 
Full details are in the industry submission, but in brief; 
 HbA1c was reduced by 1.33% in the liraglutide arm and by 0.24% in the placebo arm, 
suggesting that liraglutide reduced it by 1.09%, with the rest being trial effect. (The 
implication is that glargine reduced it by 0.85% after subtracting trial effect). 
 53.1% of patients in the liraglutide arm reached the HbA1c target of <7.0% versus 15.5% in 
the placebo arm. The baseline levels were 8.3%, which shows that 15% of the placebo group 
achieved a reduction of at least 1.3% from trial effect alone. 
 Systolic blood pressure fell by an average of 4 mmHg in the liraglutide arm and by 1.4 mmHg 
in the placebo arm, suggesting that liraglutide was responsible for a drop of 2.6 mmHg. 
 Weight was reduced by 1.8 kg in the liraglutide arm, and by 0.4 kg in the placebo arm, 
suggesting a net liraglutide effect of 1.4 kg  
LEAD-4  had the following comparisons; 
Liraglutide 1.2 mg  + metformin  + rosiglitazone 4 mg 
versus 
Liraglutide 1.8 mg + metformin +rosiglitazone 4 mg  
versus 
Placebo + metformin + rosiglitazone 4 mg 
 
LEAD-4 was a good quality trial as shown in Table 4 
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Table 5 Risk of bias table for LEAD-4 
Item Judgement Description 
Adequate sequence generation? Yes Randomised as 1:1:1. 
Telephone or web based 
randomisation; protocol states: 
"Randomisation will be carried 
out centrally using a 
randomisation system, 
IVRS/IWRS" [Interactive voice 
(or web) response system] 
Allocation concealment? Yes Telephone or web based 
randomisation 
Blinding? Yes Double blinding 
Incomplete outcome data 
addressed? 
Yes Missing data were imputed as 
the last observation carried 
forward (LOCF), ITT analysis, 
adequate description of 
withdrawals and losses to 
follow-up 
Free of selective reporting? Yes Included all prespecified 
outcomes 
Groups comparable at baseline? Yes  
Sample size calculation? Yes The combined power 
(calculated as the product of the 
marginal powers for HbA1c and 
weight) was >95% 
 
Full results are in the industry submission, but in brief; 
 HbA1c was reduced by 1.5% in the liraglutide 1.2 mg arm versus 0.5% in the placebo arm.  
The usual reduction considered to be clinically significant is 0.5%, so “placebo” i.e. the trial 
effect, was effective. Subtracting that suggests that the reduction with liraglutide 1.2 mg was 
1.0%. 
 The 1.8 mg dose of liraglutide achieved no greater effect on HbA1c than the 1.2 mg dose 
 The proportions of patients reaching the HbA1c target of <7.0% were 58% with liraglutide 
1.2 mg, 54% with liraglutide 1.8 mg, and 28% with placebo. 
 Weight was reduced by 1 kg with liraglutide 1.2 mg, by 2 kg with liraglutide 1.8 mg, and rose 
by 0.6 kg in the placebo group, suggesting net effect of a reduction of 1.6 kg with liraglutide 
1.2 mg. 
 Systolic blood pressure fell by 6.7 mm/Hg with liraglutide 1.2 mg, 5.6 mmHg with liraglutide 
1.8 mg and 1.1 mm/Hg with placebo, giving a placebo-corrected effect of 5.6 mmHg with 
liraglutide 1.2 mg and 4.5 mmHg with liraglutide 1.8 mg. 
Summary of third-line liraglutide compared to placebo 
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As expected, these trials show that liraglutide as a third line drug is effective, reducing HbA1c by 
about 1% in patients with baseline levels of 8.3 to 8.6%, accompanied by about 1 kg weight loss with 
1.2 mg and 1.4 kg with 1.8 mg of liraglutide. 
 
What dose of liraglutide? 
The standard dose of liraglutide appears to be the 1.2 mg/day dose, but some trials have used 1.8 mg. 
However, the marginal gain from the higher dose does not seem to be great.   
 
Table 6 shows HbA1c reductions from some trials 
 
Table 6 Reductions in HbA1c by dose of liraglutide 
 1.2 mg daily 1.8 mg daily 
1860 ***** **** 
LEAD-1 1.1 1.2 
LEAD-2 1.0 1.0 
LEAD-4 1.5 1.5 
 
Similarly for the proportions reaching the HbA1c target of <7.0% are shown in Table 7. The weight 
change from baseline is shown in  
Table 8 , and the changes in SBP in Table 9. 
  
Table 7 Proportions reaching HbA1c target of <7.0% 
 1.2 mg daily 1.8 mg/daily 
1860 *** *** 
LEAD-1 35% 42% 
LEAD-2 35% 42% 
LEAD-4 58% 54% 
 
 
Table 8 Weight change from baseline 
 1.2 mg 1.8 mg 
1860 ********* ******* 
LEAD-1  + 0.3 kg -0.2 kg 
LEAD-2  - 2.6 kg - 2.8 kg 
LEAD-4  - 1.0 kg -2.0 kg 
 
In the 2-year follow-up of LEAD-2 the weight loss on 1.8 mg was less (2.9 kg) than on 1.2 mg (3.0 
kg).
27
 
 
Table 9 Systolic BP change in mm Hg 
 1.2mg 1.8mg 
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1860 ****** ****** 
LEAD-1 - 2.6  -2.8 
LEAD-2 - 2.8 - 2.3 
LEAD-4 - 6.7 - 5.6 
 
Table 10 Nausea percentages (rounded) 
 1.2 mg 1.8 mg 
1860 *** *** 
LEAD-1 11% 7% 
LEAD-2 16% 19% 
LEAD-4 45% 56% 
 
As show in Table 10  the proportions of patients reporting nausea vary widely amongst the trials, from 
11% to 45% with the 1.2 mg dose and from 7% to 56% with the 1.8 mg dose.  
 
Figure 4, Figure 5, Figure 6 and Figure 7 below show meta-analyses of these variables. (These are all 
academic in confidence because the 1860 results could be deduced if the others were given.) 
* 
Figure 4 Change in HbA1c from baseline liraglutide 1.2 mg versus 1.8 mg 
 
* 
Figure 5 Patients reaching HbA1c <7% liraglutide 1.2 mg versus 1.8 mg 
 
* 
Figure 6 Change in weight from baseline liraglutide 1.2 mg versus 1.8 mg 
 
* 
Figure 7 Change in systolic blood pressure from baseline liraglutide 1.2 mg versus 1.8 mg 
 
So the only statistically significant difference is in weight, where the difference is of doubtful clinical 
significance. 
 
More details of the effects of liraglutide 1.2 and 1.8 mg doses are given in Appendix 3. 
 
So we might expect 1.2 mg daily (as in the industry submission) to be the standard dose. This was the 
conclusion of the EMEA assessment report;
28
 
“It is concluded that in dual and combination treatment, only limited effect can be expected from an 
increase in dose to 1.8 mg, while GI adverse events might increase.” 
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The submission from Novo Nordisk states on page 42, that, 
“It is anticipated that liraglutide 1.2 mg will be used in the majority of patients.” 
 
However the EMEA EPAR report noted that there might be an advantage of the bigger dose in the 
heaviest patients (over 90 kg) in whom the reduction in HbA1c was greater (EPAR page 33).
28
 
 
Unfortunately, in two trials against active comparators, LEAD-6 versus exenatide, and LEAD-5 
against glargine, only the 1.8 mg dose was used.  Contact with the manufacturer confirms a lack of 
data on the relative effectiveness of the 1.2 mg dose against these drugs. This creates a problem for 
the cost-effectiveness modelling because the larger dose is much more expensive (by about 50%) but 
may not be significantly more effective. 
 
During the appraisal period, Novo Nordisk arranged for some indirect comparisons to be done, so that 
results from LEAD trials 1 to 4, and the unpublished trial against sitagliptin, could be used to simulate 
what would have happened had there been such arms in LEAD-5 and LEAD-6.  
 
The predicted mean reduction in HbA1c in LEAD-5 had the 1.2 mg dose been used, was 1.19% (SE 
0.02, so 95% CI 1.15 to 1.23%) compared to the observed reduction with glargine of 1.09%. 
Compared to the 1.8 mg dose, the reduction with 1.2 mg would be 0.11% less, with the 95% 
confidence intervals not quite touching (upper bound for 1.2 mg, 1.23%, lower for 1.8 mg, 1.24%). 
In LEAD-6, the predicted reduction with 1.2 mg was 1.08% (1.02 to 1.14%) compared to the 
observed reduction with exenatide of 0.79%. 
 
It would be better if we had direct comparisons, because indirect comparisons could be prone to 
unknown confounding variables. However in the absence of direct comparisons, the indirect 
comparison is useful. The methods seem appropriate, and our only concern is that the method applies 
the predicted effect of the 1.2 mg dose to all patients in the LEAD-5 and LEAD-6, so that the 
confidence interval is reduced. 
3.2 Liraglutide as second drug 
Three trials compared liraglutide as second drug. 
LEAD-1 
LEAD-1 was used in patients who had inadequate glycaemic control with glimepiride (a 
sulphonylurea). It compared liraglutide with rosiglitazone (a thiazolidinedione) as second drug. There 
Copyright 2010 Queen's Printer and Controller of HMSO. All rights reserved.
36 
 
was also a placebo arm. All three arms were on glimepiride as well.  Baseline BMI ranged between 29 
and 31 while baseline HbA1c between 8.4 and 8.5. 
 
LEAD-1 was scored quite well in our quality assessment as shown below in Table 11 , but has been 
criticised for using a rosiglitazone dose of only 4 mg daily. The EMEA report (page 30) also noted 
that the trial lasted 26 weeks, which might not allow rosiglitazone to reach its full effect.
28
 . It could 
also be argued that pioglitazone would have been better, since it has a more favourable risk profile 
than rosiglitazone.  Both can cause heart failure and fractures, but rosiglitazone appears to slightly 
increase cardiovascular mortality, whereas pioglitazone reduces it. In a recent UK study in 91,521 
people with diabetes, rosiglitazone was associated with a 34% to 41% higher risk of all cause 
mortality compared to pioglitazone.
29
  Some regulatory bodies have now placed warnings on 
rosiglitazone use. 
 
Table 11 LEAD-1 risk of bias table  
Item Judgement Description 
Adequate sequence generation? Unclear Subjects were stratified 
according to previous treatment 
(monotherapy or combination 
therapy) 
Allocation concealment? Unclear Insufficient information 
Blinding? Yes Double blinding 
Incomplete outcome data 
addressed? 
Yes Missing data were imputed as 
the last observation carried 
forward (LOCF), ITT analysis, 
adequate description of 
withdrawals and losses to 
follow-up 
Free of selective reporting? Yes Included all pre-specified 
outcomes 
Groups comparable at baseline? Yes  
Sample size calculation? Yes A combined power (calculated 
as the product of the marginal 
powers for HbA1c and body 
weight) of at least 85% was 
required. 
 
Full details are in the industry submission, but in brief, 
 HbA1c was reduced by 1.08% in the liraglutide 1.2 mg arm and 1.19% in the liraglutide 1.8 
mg arm, and in the rosiglitazone 4 mg arm by only 0.44%.  It rose by 0.23% in placebo arm. 
 Weight was reduced by 0.2 kg and 0.1 kg in the liraglutide 1.8 mg and placebo arms 
respectively. In the liraglutide 1.2 mg and rosiglitazone arms, it increased by 0.3 kg and 2.1 
kg respectively. 
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 Systolic BP decreased in the range of 2.6 to 2.8 mmHg in the liraglutide 1.2 and 1.8 mg arms 
while the reduction in the placebo and rosiglitazone arms was between 0.9 to 2.3 mmHg.  
So compared to rosiglitazone 4 mg, there was a significant difference in HbA1c but no difference in 
weight and SBP. However note that this was with rosiglitazone 4 mg daily. 
LEAD-2 
LEAD-2 was in patients inadequately controlled on metformin alone, and compared liraglutide with 
glimepiride as second drugs. The NICE guidelines do not  recommend a  GLP-1 agonist as second-
line drug. There was also a metformin and placebo arm. Baseline BMI was about 31 and baseline 
HbA1c about 8.4% 
 
LEAD-2 was a good quality trial as show in Table 12. It lasted 26 weeks. 
 
Table 12 LEAD-2 risk of bias table 
Item Judgement Description 
Adequate sequence generation? Yes Randomly assigned as 
2:2:2:1:2. Telephone or web 
based randomisation. Patients 
randomly assigned to the lowest 
available randomization number 
and stratified with respect to 
their previous use of OAD 
monotherapy or combination 
therapy 
Allocation concealment? Yes Telephone or web based 
randomisation 
Blinding? Yes Double blinding 
Incomplete outcome data 
addressed? 
Yes Missing data were imputed as 
the last observation carried 
forward, ITT analysis, adequate 
description of withdrawals and 
losses to follow-up  
Free of selective reporting? Yes Included all expected outcomes, 
including those prespecified 
Groups comparable at baseline? Yes  
Sample size calculation? Yes The combined power 
(calculated as the product of the 
marginal powers for A1C and 
weight) was at least 85% 
 
Full details of the results are in the industry submission, but in brief; 
 HbA1c was reduced by 1% in the liraglutide 1.2 and 1.8 mg arms, and in the glimepride 
group. It rose by 0.1% in the placebo group 
Copyright 2010 Queen's Printer and Controller of HMSO. All rights reserved.
38 
 
 Weight was reduced by 2.6 and 2.8 kg in the liraglutide 1.2 and 1.8 mg groups, and by 1.5 kg 
in the placebo group, giving placebo-adjusted losses with liraglutide of 1.1 and 1.3 kg. 
Weight rose by 1 kg with glimepiride. 
 Systolic BP fell by 2.8 mmHg in the 1.2 mg liraglutide arm, by 2.3 mmHg in the 1.8 mg arm, 
and by 1.8 mmHg in the placebo arm. It rose by 0.4 mmHg in the sulphonylurea arm. Hence 
the placebo-adjusted SBP reductions with liraglutide were 1 and 0.5 mmHg. 
So compared to glimepiride, no difference in HbA1c but weight advantage of 3.7 kg and SBP 
difference of  3.2 mmHg. 
1860 
NN2211-1860 was a randomised, active-comparator trial designed to compare the efficacy and safety 
of liraglutide with liraglutide 1.2 mg or 1.8 mg once-daily with sitagliptin 100 mg once-daily. All 
groups continued on metformin therapy. The trial was run in 158 sites across 13 countries and 
duration was 26 weeks. The primary endpoint was the change in HbA1c from baseline. 
The inclusion criteria of participants were: aged 18–80 years with type 2 diabetes, HbA1c of 7.5–
10.0% (prestudy, stable metformin therapy ≥1500 mg for ≥3 months) at screening and BMI ≤45.0 
kg/m
2.   
A total of *************were randomised and ****completed the trial. The mean baseline 
characteristics were age **********HbA1c =*******weight *********and SBP 
**************As shown in Table 13, 1860 was a good quality trial. 
 
Table 13 1860 risk of bias table 
Item Judgement Description 
Adequate sequence generation? Yes Computer generated random 
numbers 
Allocation concealment? Yes Local randomisation. Patients 
were randomly assigned to the 
lowest available randomisation 
number by the site investigator 
Blinding? No Open label 
Incomplete outcome data 
addressed? 
Yes  
Free of selective reporting? Yes  
Groups comparable at baseline? Yes  
Sample size calculation? Yes  
 
Full details of the results are in the industry submission, but in brief; 
**********************************************************************************
**********************************************************************************
**********************************************************************************
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**********************************************************************************
**********************************************************************************
**********************************************************************************
**********************************************************************************
**********************************************************************************
**********************************************************************************
**********************************************************************************
**********************************************************************************
**********************************************************************************
**********************************************************************************
****************************************************** 
 
Is there a case for second-line use of liraglutide? 
The industry submission (page 40) suggests that dual therapy with liraglutide and either metformin or 
sulphonylurea would be of benefit in a number of situations. These, followed by our comments in 
italics, are; 
 Patient choice favours liraglutide as second-line therapy: but patient choice should not take 
precedence over cost-effectiveness 
 Other incretin-based therapies are not expected to provide sufficient glycaemic control: but 
other GLP-1 therapies would be 3
rd
 line (as per NICE guidelines) 
 Weight loss would benefit other significant obesity-related comorbidities: a valid point 
 Weight gain would be undesirable and result in a degenerative effect on other medical issues: 
this presumably refers to the fact that use of sulphonylurea, glitazone or insulin is usually 
associated with weight gain. However the gliptins are weight neutral, taken orally, and much 
less expensive and with fewer side-effects than liraglutide. 
 There is a risk related to hypoglycaemia elicited by alternative therapies: not a problem with 
the gliptins 
 The routine use of SMBG is difficult or not possible: but only justified with insulin, not 
usually with other oral agents, unless there are problems with hypoglycaemia with 
sulphonylureas. 
 Patients have existing cardiovascular disease: might be a contraindication for the use of 
rosiglitazone, and of pioglitazone if heart failure an issue, but not for use of gliptins or insulin 
 Patients have medical problems associated with high body weight, such as obstructive sleep 
apnoea: weight loss does benefit obstructive sleep apnoea, but the amount of weight loss 
required is much greater than is seen in most patients in the liraglutide trials. A recent study 
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by Foster and colleagues showed that major improvements in sleep apnoea were seen mainly 
in those who lost over 10kg.
30
 
 
3.3 Some other issues 
 
The liraglutide meta-analyses. 
No meta-analyses were included in the industry submission, on the grounds that it was not appropriate 
due to different concomitant medications. However meta-analyses of the six LEAD trials, sponsored 
by Novo Nordisk, have appeared in abstract form at the 2009 World Diabetes Congress but mainly for 
the 1.8mg dose, since some of the trials did not have 1.2mg arms. The results at 26 weeks included; 
 Total cholesterol was reduced by 0.13 mmol/l, compared to a drop of 0.01 on placebo, 0.05 
on glimepiride, and a rise of 0.02 on glargine. 
31
 
 LDL cholesterol fell by 0.2 mmol/l on liraglutide 1.8 mg, and by 0.13 on placebo, giving a net 
drop of 0.07 on liraglutide. It fell by 0.07 on glargine and by 0.15 on exenatide. 
31
 
 Triglycerides fell by 0.20mmol/l on liraglutide 1.8mg, by 0.15 mmol/l on glargine, and rose 
by 0.02mmol/l on placebo. 
31
 
 Weight loss varied. On 1.8mg liraglutide, 24% of people lost no weight (some gained); 35% 
lost under 3% of baseline weight; 17% lost between 3 and 5%; and 24% lost over 5%. Note 
that 10% of those on placebo also lost over 5%. 
32
 
 The reduction in HbA1c was greatest in those who lost most weight (1.65% reduction in 
HbA1c), but even in those who lost no weight, HbA1c fell, by 1.38%.
32
 
Which insulin should be the comparator?  
The 4T trial showed that on balance, the choice of insulin for patients starting it because glycaemic 
control was not good enough on a combination of oral drugs, was basal insulin, rather than short-
acting mealtime insulins or twice daily mixtures.
33,34
 So the correct comparator for liraglutide is a 
once daily basal insulin.  According to the NICE guideline, that should be NPH, because the 
advantages of the long-acting analogues are slight and the cost much greater, giving high costs per 
QALY. 
 
However, practice in the UK has moved away from NPH, and the most commonly used basal insulin 
is now glargine, with detemir also overtaking NPH.
5
  Hence Novo Nordisk could make a case that 
using glargine as the comparator was simply recognising the realities in the NHS. Note also that 
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LEAD-5 was carried out in 17 countries. Nevertheless, when it comes to cost-effectiveness analysis, 
the extra cost of glargine compared to NPH will be important. 
 
Curiously, the LEAD-5 trial, sponsored by Novo Nordisk, used the Sanofi-Aventis insulin glargine, 
rather than the Novo Nordisk one, detemir.  
 
What should the GLP-1 analogue comparator be? 
The only other currently available GLP-1 analogue is twice daily exenatide.  However we know that 
the once weekly exenatide LAR is being submitted to FDA in 2010,
35
  and that other long-acting 
GLP-1 analogues such as albiglutide and taspoglutide are in the pipeline, with trials published.
36,37
 
Also, trials on lixisenatide are currently recruiting patients.
38,39
  We also know that a trial of weekly 
exenatide versus daily liraglutide, DURATION-6 is being launched.
40
 
 
Hence modelling liraglutide against twice daily exenatide seems unrealistic.  However, NICE will not 
consider unlicensed medicines, and we have no price as yet for exenatide LAR, so modelling has to be 
done against twice daily exenatide. 
 
GLP-1 and insulin combinations 
At present, neither exenatide nor liraglutide is licensed for use in combination with basal insulin. 
However trials are underway or have been done,
41-44
 and the combination looks very logical, given 
that the GLP-1s act mainly on post-prandial hyperglycaemia, and basal insulin on fasting and pre-
prandial.  The combination might therefore give better glycaemic control while avoiding rises in 
weight and blood pressure. 
 
So future use will probably include GLP-1 analogue and insulin combinations. 
 
Safety: thyroid cancer and pancreatitis 
Safety is an issue for the MHRA rather than NICE, and only brief notes are included here. 
There has been concern about the effects on the C cells of the thyroid gland after C-cell tumours were 
observed in mice and rats. The data have been reviewed intensively in both the FDA and the EMEA 
appraisal processes.  It has been noted that there are more GLP-1 receptors in rat thyroid cells than in 
human ones, and the EMEA concluded that, 
 “The relevance for humans is likely to be low but cannot be completely excluded.”28 
 
In the human trial, the rate of thyroid adverse effects appears to be higher with liraglutide than with 
non-liraglutide treatments (about 36 vs 22 events per 1000 patient year – EMEA EPAR page 38).  
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Malignant thyroid neoplasms were slightly increased with liraglutide (10.9 for all liraglutide  vs 6.9 
for all comparators) but the incidence rates were no higher than in the US background population. 
The hormone calcitonin comes almost entirely from thyroid C-cells and can be used as a marker for 
increase C-cell activity.  Data from the trials show that calcitonin levels increased, particularly with 
liraglutide 1.8 mg (at week 26) but the levels stayed mostly within the normal range, which is 
reassuring. 
 
There have been reports of pancreatitis with exenatide but because the incidence of pancreatitis is 
increased in type 2 diabetes, it has proved difficult to show whether there is a true increase in a rare 
event with exenatide. 
45
 The liraglutide trial data show a slight increase in pancreatitis in those on 
liraglutide compared to oral comparators (1.6 vs 1.4 per 1000 patient years) but this should be set 
against the background rate of 1 to 5 per 1000 patient years in type 2 diabetes. 
 
The long-term effects will require to be monitored, given the short-term nature of the trials, but the 
MHRA does not appear to be concerned about these issues at present. The FDA has taken a more 
cautious line.
46
 
 
Beta –cell function 
It has been suggested by the manufacturer (NN synopsis 2009)  that liraglutide might prevent 
progression of type 2 diabetes by preserving beta-cell function.  Beta-cell function was estimated in 
some of the trials using HOMA-B or the pro-insulin to insulin ratio, and much greater responses were 
seen with liraglutide than with rosiglitazone or glimepiride. Interestingly, the improvement was 
greater with liraglutide 1.2 mg than the 1.8 mg dose. However, these results are based on short-term 
trials, and it is not known whether any effect would be sustained after liraglutide was stopped. The 
evidence with exenatide is that the effect is not sustained.  
 
The effect on beta-cell function therefore remains uncertain, and the industry submission makes no 
claims about it. 
 
3.4 Conclusions on clinical effectiveness 
Liraglutide appears to be a safe and effective drug which improves glycaemic control, accompanied 
by reductions in weight and systolic blood pressure.  
 
The 1.2 mg dose appears to be sufficient for most patients, since the marginal effects of the 1.8 mg 
dose are slight. 
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4. REVIEW OF ECONOMIC MODELLING OF 
LIRAGLUTIDE  
 
4.1 Economic literature review 
 
One study was found, by Sullivan and colleagues 2009. 
47
 This was a study sponsored by Novo 
Nordisk, and with co-authors from the company. It was based only on the LEAD 1 trial, which was of 
dual therapy, not all costs were included, and the perspective was from a US health care payer one. It 
used the CORE model. We think this study is superseded by the industry submission, and it is not 
included here. We note the comment in the industry submission (page 45) on the Sullivan study that: 
“Due to the setting chosen and the exclusion of drug costs, the study does not give an indication of 
total treatment costs to the NHS or the cost-effectiveness of liraglutide.” 
 
4.2 The CORE model 
The industry submission uses the well-developed CORE (Center for Outcomes Research) model 
which has been used for many studies in the past. Many of these have been sponsored by industry and 
have produced results with which we might not agree. But we have no problems with the model itself. 
A description of the model and its validation has been attached as appendix 4.4.  
 
It does not meet the criteria for acceptability by NICE, on a number of grounds, such as software used 
and transparency. However diabetes is a very complex disease, and it would have been wasteful for 
Novo Nordisk to have commissioned a new model in one of diabetes. NICE therefore, with our 
agreement, allowed the use of this non-standard software. Precedents have been set in previous 
appraisals of diabetes topics, with CORE used in the insulin pumps appraisal, and EAGLE in the 
inhaled insulin one. 
 
In brief, we consider the CORE model to be satisfactory. 
 
4.3 ERG cross check of modelling inputs 
 
Population baseline characteristics 
The baseline population characteristics outlined in table 16 [p52] of the submission correspond with 
those applied for the base case modelling within CORE. 
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Principal clinical effectiveness estimates 
The estimates of clinical effectiveness for the trial population as a whole as tabled in appendix 9 of 
the submission, as outlined in the review of clinical effectiveness, have been cross checked with the 
clinical trial reports and corresponded with the ANCOVA analysis of change for all values, though 
note that this is distinct from the Summary of Change  ITT Analysis Set.  
 
For the modelling within CORE the parameter values of appendix 9 correspond with the base case 
input parameters with the following exceptions around hypoglycaemic event rates for trial 1860. 
 
Table 14 Differences between CORE and industry submission 
1860 Hypoglycaemic events Liraglutide 1.2mg Liraglutide 1.8 mg Sitagliptin 100mg 
Severe/100 patient years 
Submission 
CORE modelling 
 
* 
1.05 
 
* 
0 
 
* 
0 
Minor/100 patient years 
Submission 
CORE modelling 
******* 
18.89 
******* 
38.05 
******* 
11.62 
 
**********************************************************************************
**********************************************************************************
********************** 
 
Note that clinical effectiveness estimates for the subgroup analyses of those with BMI >30kg/m
2
 and 
of those with BMI > 35kg/m
2
 have not been checked as these were further analyses undertaken by the 
manufacturer with no external source to cross check against. 
 
Modelling of therapy change at end of year 5 
Because type 2 diabetes is a progressive disease, intensification of treatment is usually necessary over 
time, as beta cell function declines. The baseline case in the industry model assumes that liraglutide 
will only be effective for 5 years, and this seems reasonable. (We made similar assumptions for 
exenatide in our review for the NICE Type 2 diabetes Guidelines Group). 
 
It appears that for the weight changes for those moving on to glargine after 5 years on liraglutide, only 
the direct disutility from this has been applied. The effect upon BMI and subsequent complications 
within the CORE modelling appears to have assumed that BMI progression is unaffected by the move 
on to glargine. 
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Also, within the simulations for most trials, the move to glargine is associated with little clinical 
effect: as per figure 8 [p58] and figure 9 [p59] of the submission. The exception to this was the step 
change in the direct disutility due to the BMI increase as per figure 10 [p59] as has been discussed 
above: as this was a common step change to both arms it appears to have had little net effect.  
 
Initial liraglutide 1.8 mg was associated with the following changes from baseline at the start of year 
1. 
 
Table 15 Changes from baseline in LEAD-5 - liraglutide 
Changes with liraglutide 1.8mg MEAN: SD: 
    HbA1c -1.33 %points 1.35 %points 
     SBP -3.97 mmHg 19.61 mmHg 
     T-Chol -2.36 mg/dl 41.31 mg/dl 
     LDL 4.19 mg/dl 35.17 mg/dl 
     HDL -2.32 mg/dl 9.58 mg/dl 
     TRIG -21.79 mg/dl 149.22 mg/dl 
     BMI -0.644 kg/m2 1.373 kg/m2 
 
Glargine was associated with the following changes (table 16). 
 
Table 16 Changes from baseline in LEAD-5 - glargine 
Changes with glargine 
 MEAN: SD: 
    HbA1c -1.09 %points 1.377 %points 
     SBP 0.54 mmHg 20.345 mmHg 
     T-Chol 2.77 mg/dl 42.679 mg/dl 
     LDL 9.15 mg/dl 36.254 mg/dl 
     HDL -2.07 mg/dl 9.943 mg/dl 
     TRIG -19.52 mg/dl 153.888 mg/dl 
     BMI 0.577 kg/m2 1.495 kg/m2 
 
It could be argued that the change from liraglutide to glargine at year 5 should be accompanied by 
changes similar to those seen with glargine in year 1, because the change is necessary because of 
progression of disease due to falling beta cell function, and hence increasing insufficiency of 
endogenous insulin. So when glargine is started, one would expect at least as big an effect as in year 1 
in the glargine arm. 
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The ERG applied the above glargine changes to both arms within the 1860 and the LEAD-6 
modelling. This had no impact upon results, which suggests that there may be a problem within the 
CORE model in the implementation of the relatively new feature of being able to specify second line 
treatments. This is strange given that associating second line treatments with a treatment disutility and 
a cost has an impact upon results. Correspondence with the Novo Nordisk team, and the independent 
consultant  nominated by the manufacturer, who previously worked for IMS, suggests that in the 
CORE model, the switch incorporates changes in cost and disutility, but not improvements in 
glycaemic control.  
It has not been possible to sort out the implications of this in the time available, and enquiries are 
continuing. Neither the ERG nor the manufacturer has access to the inner workings of CORE, but just 
the web-based “front end”.  
However, if the effect is that the model does not give patients initially treated with liraglutide, an 
improvement in HbA1c when they switch to insulin after (an assumed and average) five years, then 
liraglutide may be somewhat disadvantaged. 
 
Other clinical inputs to the CORE model 
The values of tables A-6 and A-7 of Appendix 6 of the submission were cross checked with those 
implemented within the CORE modelling, and a few discrepancies were found  
 
Table 17 Discrepancies within industry submission 
 Submission CORE modelling 
Prop. 2° prevention: ACEi 0.21 0.58 
Sensitivity eye screening 0.76 0.80 
Specificity eye screening 0.99 0.97 
Sensitivity GPR screening 0.95 0.85 
Sensitivity MAU screening 0.85 0.75 
Specificity MAU screening 0.85 0.97 
However these appear to be relatively minor. 
 
It should be noted that the manufacturer amended some of the CORE default values, to make them 
more applicable to the UK, given that the CORE default values are apparently not UK specific. The 
changes made relate to concomitant medication and the proportions being screened. 
 
Table 18 Manufacturer’s amendments to CORE default values. 
 CORE default CORE amended Difference 
Concomitant medication 
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Prop 1° prevention ASP 10% 8% -2% 
Prop 2° prevention ASP 50% 8% -42% 
Prop 1° prevention Statins 0% 18% 18% 
Prop 2° prevention Statins 50% 18% -32% 
Prop 1° prevention ACE-I 15% 58% 43% 
Prop 2° prevention ACE-I 50% 58% 8% 
Screening and patient management proportions 
Prop on foot ulcer prevention program 30% 37% 7% 
Prop screened eye disease 75% 63% -12% 
Prop screened for renal disease 75% 60% -15% 
Prop receiving intensive insulin after MI 20% 100% 80% 
Prop treated with extra ulcer treatment 50% 50% 0% 
 
The amended proportion treated with short-term insulin after MI may be optimistic. 
The impact of these changes has not been explored by the ERG. Preventive use of statins apparently 
mainly affects the cardiovascular risks within the CORE model, and higher 1
st
 line use may tend to 
work against the treatment with the superior cardiovascular risk profile. ACE inhibitors apparently 
also have a renal protective function within the modelling, and given the expense of renal disease 
higher 1
st
 line use may similarly tend to work against the more effective treatment. 
 
The lower proportions being screened appear likely to increase the impact of better disease control 
and so may tend to improve the cost effectiveness estimates for liraglutide. 
 
Note also that the CORE default specifies a 43% probability of death from a lactic acidosis event. 
Within the manufacturer modelling this was set to zero. 
 
Drug dosing and direct treatment costs 
1
st
 line treatment costs: 
As outlined in appendix 7 of the submission, the drug costs and ancillary equipment costs associated 
with the 1
st
 line treatments within the submission were as below: 
 
Table 19 Costs for 1860 trial arms 
1860 trial Liraglutide 1.2mg Liraglutide 1.8mg Sitagliptin 100mg 
Concomitant treatment costs £18.12 £18.12 £18.12 
Annual drug costs £954.84 £1,432.26 £433.57 
Cost of needles £31.10 £31.10  
SMBG £0.00 £0.00 £0.00 
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Total annual treatment costs £1,004.06 £1,481.48 £451.69 
Within the above, the cost of sitagliptin 100mg and one snap on needle per day cross check with BNF 
58. 
 
Table 20 Costs for LEAD-6 arms 
LEAD6 trial Liraglutide 1.8mg Exenatide 10μg 
Annual drug costs £1,432.26 £830.25 
Cost of needles £46.65 £93.29 
SMBG £51.09 £51.09 
Total annual treatment costs £1,530.00 £974.64 
 
Within this, the cost of exenatide 10μg bid  cross checks with BNF 58.  Liraglutide and exenatide are 
assumed to require three testing strips per week for the self monitoring of blood glucose, which again 
broadly cross checks with BNF 58.  However this may be more than is required since the evidence for 
the benefits of SMBG in people with type 2 diabetes, not treated with insulin, is unproven. A 
forthcoming Department of Health working group report will recommend that there might be a case 
for some use in those on sulphonylurea and who are having significant problems with hypoglycaemia. 
However, the industry submission is in line with guidelines from bodies such as International 
Diabetes Federation. 
48
 The evidence is reviewed in a forthcoming HTA report on the use of SMBG in 
non-insulin-treated type 2 diabetes. 
49
 Reducing the number of strips used would not affect the 
liraglutide versus exenatide comparison, but would have a slight effect on the comparison with 
glargine, by reducing the liraglutide costs. 
 
The reason for the slightly higher needle cost for liraglutide 1.8 mg within LEAD-6 as compared to 
1860 is not clear, but the effect is minor. Perhaps more questionable, while liraglutide has the 
advantage of once daily dosing as compared to twice daily dosing for exenatide is whether patients 
routinely change needles for every dose. An alternative assumption of one needle per day would 
reduce the annual cost of exenatide by £46.65 [5%] to £927.98. 
 
For the LEAD-5 trial the submission listed the following drug costs. 
 
Table 21 Costs for LEAD-5 arms 
LEAD-5 trial Liraglutide 1.8mg Glargine 24 IU Glargine 40 IU 
Concomitant treatment costs £77.63 £80.58 £80.58 
Annual drug costs £1,432.26 £235.70 £392.84 
Cost of needles £46.65 £46.65 £46.65 
SMBG £51.09 £119.21 £119.21 
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Total annual treatment costs £1,607.62 £482.14 £639.27 
 
The above costs for glargine cross check with BNF 58, with the submission assuming that glargine 
requires one daily testing strip for the self monitoring of blood glucose. 
 
Within the above, it should be noted that the end of trial average daily glargine dose was 24 IU. The 
base case of the modelling submitted by the manufacturer assumed that this would apply during the 
first year, but that for the second and subsequent years an average daily dose of 40 IU would be 
required.  
 
Titration of the glargine dose may increase the average dose, but as outlined in the clinical review 
section of this report there may be some concerns around the effectiveness of the titration of glargine 
within the LEAD-5 trial. While increasing the dose would increase the first year drug costs within the 
glargine arm, it might also have led to an improved effectiveness for the glargine arm. The 
assumption within the submission of a 40 IU average dose in the second and subsequent years 
increases the costs within the glargine arm without applying the possible patient benefits of this 
titration. 
 
The manufacturer also outlined the possible costs of insulin therapy if NPH was assumed to have been 
used. 
 
Table 22 Costs in LEAD if NPH used 
LEAD5 trial Liraglutide 1.8mg NPH 24 IU NPH 40 IU 
Concomitant treatment costs £77.63 £80.58 £80.58 
Annual drug costs £1,432.26 £111.43 £185.71 
Cost of needles £46.65 £46.65 £46.65 
SMBG £51.09 £119.21 £119.21 
Total annual treatment costs £1,607.62 £357.86 £432.15 
 
Again, save for very minor differences in the NPH costs which are possibly due to the balance 
assumed between NPH formulations, these cross check with BNF 58. If NPH can be viewed as 
equivalent to glargine in terms of outcomes this would result in the insulin arm being somewhat less 
costly: £124 [26%] in the first year, and £207 [33%] in the second and subsequent years. 
 
The rosiglitazone costs cross check with a 4 mg daily dose and the glimepiride costs cross check with 
a 4 mg daily dose of non-proprietary glimepiride in BNF 58.  
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Future treatment costs: 
With the exception of the glargine arm in the modelling of the LEAD5 trial, after therapy change at 
the end of the fifth year, patients were assume to progress to glargine at an annual direct treatment 
cost of £638.05. This broadly corresponds with the annual cost of the glargine arm for the second and 
subsequent years of the LEAD-5 modelling of £639.27. 
 
Costs of complications 
The costs derived from UKPDS 65 cross checked with those given in UKPDS 65.
50
 As outlined in 
greater detail in Appendix 8, the application of the outpatient costs within this may have resulted in 
some double counting. But there is no obvious means within the CORE model structure of avoiding 
this. Given the sensitivity analysis around price indexation as reported below, any double counting of 
outpatient costs appears unlikely to have significantly affected the analysis. 
 
The drug management costs within table 19 [p53] cross check with BNF 58. Note that while table 19 
suggests that the non-standard Regranex ulcer treatment is a monthly cost, as implemented within the 
CORE modelling of the submission it appears to be a one off use of one tube of Regranex. 
 
Note that these costs are also reported within appendix 13 of the submission, with there being 
divergence between this and table 19 in the costs of aspirin, statins, ACE-I, screening for 
nephropathy, screening for retinopathy and the cost of a non-standard ulcer. The costs implemented 
within CORE cross check with those of table 19, though note that within CORE screening costs for 
microalbuminuria and retinopathy are combined to a single cost of £36, and foot screening and GRP 
screening are similarly combined to a cost of £23. 
 
The costs derived from UKPDS 40 cross checked with those given in UKPDS 40 where these could 
be identified.
51
 But the ERG was not able to locate the £20,000 costs of renal transplant within this, or 
the £6,500 annual costs subsequent to renal transplant: £22,191 and £7,212 respectively once indexed 
to 2008. 
 
The costs derived from the Ghatnekar 2001 reference
52
 (Table 23 of the submission [p54] suggests a 
2000 paper, but the reference list refers to the 2001 paper) cross check with those of the submission, 
given an exchange rate of $1.62/£ resulting in: 
 £1,251 per uninfected ulcer 
 £1,282 per infected ulcer 
 £2,060 for gangrene 
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It should be noted that these are reported as being monthly recurrent costs within the Ghatnekar paper, 
the implicit assumption within the submission appearing to have been that the complications would be 
limited to one month’s duration. It should also be noted that the Ghatnekar paper:52 
 the Ghatnekar paper appears to have received industry support for a cost effectiveness 
analysis of Becaplermin 
 cost data was collected in the UK from 3 physicians using Delphi style interviews; and 
 due to poor data the Ghatnekar paper applied Swedish inpatient costs to the UK setting. 
 
The cost of £377 per severe hypoglycaemic episode was drawn from the Leese paper: £412 once 
indexed to 2008. As discussed within CG87 this cost refers to the cost per severe hypoglycaemic 
episode  requiring medical attention. CG87 assumed that only 25% of severe hypoglycaemic episode 
would require external medical assistance, with a parallel reduction in the average cost per severe 
hypoglycaemic episode. The cost per eye screen is roughly in line with that reported in the Tu 2004 
paper, which reports a cost of £24 per screen for optometrists and £29 per screen for digital 
photography. The costs of foot screening are similarly roughly in line with the Ray and colleagues 
paper,
53
 though it should be noted that this was a multi-nation study that did not include the UK. 
 
An obvious parallel 2008-09 cost to the 2007-08 £897 non-elective tarriff per ketoacidosis event of 
table 21 [p54] could not be located within the 2008-09 non-elective tariffs by the ERG. 
 
The management costs and the costs of complications as outlined in table A-8 of Appendix 6 of the 
submission cross checked with those implemented within the CORE model. 
 
Utilities 
A key utility within the submission was the -0.0100 utility decrement per unit of BMI increase as 
drawn from the Lee and colleagues paper.
54
 The submission expressed an explicit preference for this 
decrement rather than the decrement of -0.0061 per unit of BMI as used within CG87. The 
manufacturer justification for the choice of Lee appears to be that it was collected from a UK 
population. But to the extent that the CG87 decrement was reasonable, applying it would have had the 
advantage of improving the comparability between assessments. 
 
The Lee paper was only concerned with estimating the association between quality of life and BMI 
among three groups of hospital patients: the general population, patients with type 1 diabetes and 
patients with type 2 diabetes. For the subgroup of patients with type 2 diabetes, the Lee paper 
modelled quality of life as being a function of the intercept (0.9157), age (-0.0008) and BMI (-
0.0100). As such, the overall effect of BMI will have included the direct quality of life impact of 
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changes in BMI and the impact of the complications of diabetes. Since rates of complications of 
diabetes will tend to covary positively with both the BMI and the age of patients, the Lee BMI 
coefficient seems likely to reflect the direct BMI impact and some of the impact of diabetes 
complications. Consequently, within a modelling exercise such as CORE which explicitly and 
individually accounts for the disutilities associated with the complications of diabetes the Lee estimate 
of the impact of BMI will tend to double count these. 
 
Consequently, for the base case it might have been better to have used a source for utilities which 
undertook a multivariate modelling of the impacts of the complications of diabetes and BMI upon 
quality of life. This might also argue for adoption of the CG87 disutility for the base case estimate of 
the impact of BMI upon quality of life, although it is acknowledged that this value was used in the 
sensitivity analysis. 
 
The utilities reported in table 24 as being drawn from Clarke and colleagues 2002
50
 largely cross 
check with those reported in Table 2 of the paper, relating to the Clarke tobit modelling of EQ-5D 
evaluated using the social tariff. The exceptions to this are those relating to amputation, which within 
the corresponding column of the Clarke paper are decrements of -0.538 for the year of the event and -
0.412, or a utility value of 0.402, for amputations for years 2+. This compares to the values of a 
decrement of -0.109 for the year of amputation and a utility of 0.680 for amputations for years 2+ 
reported within table 24 of the submission. The values for amputation used within the submission 
relate to the Clarke modelling using the visual analogue scale. Given these values the submission is 
more optimistic as to the effects of amputation, the effect of this probably being to the slight 
disadvantage of the more effective treatment. 
 
Table 24 of the submission also makes extensive references to Palmer and colleagues for the utilities 
relating to eye disease, neuropathy and ulcer.
55
 The paper cited is a validation exercise for the CORE 
model and as such does not appear to report any utility values. The other Palmer references for section 
7 of the submission also do not appear to be papers estimating the utilities associated with these 
complications. 
 
The Tengs and Wallace 2000 paper is a literature survey of quality of life values.
56
 Within this there 
are a number of utility values reported for the likes of dialysis and the manufacturer appears to have 
made a reasonably pragmatic choice as to the utility values to apply from among these. However, it 
can be noted that Bagust and Beale
57
 in a multivariate analysis estimated the impact of peripheral 
vascular disease as involving around a 10% loss in quality of life for those with type 2 diabetes, while 
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Coffey suggested a loss of between 10% and 15% due to dialysis among those with type 2 diabetes.
58
 
As such, the values used within the submission may tend towards the high side. 
 
The decrements reported for hypoglycaemic events cross check with those reported in the submission. 
 
The BMI disutilities for the base case runs as reported in appendix 11 tally with those implemented 
within CORE for the base case 1
st
 line and 2
nd
 line treatments across the five studies. 
 
4.4 ERG cross check of results: Base Case Modelling 
The base cases within the submission have been re-run within CORE by the ERG. The output of this 
modelling corresponded with that of the submission. Appendix 4 of this report tabulates these outputs, 
augmenting those of the submission with the undiscounted survival estimates and further details as to 
the shape of the associated CEACs. The central estimates are tabulated below: 
 
Table 23 Central estimates for ICERs 
 Liraglutide 1.2 mg vs comparator Liraglutide 1.8 mg vs comparator 
 Δ£ ΔQALY ICER Δ£ ΔQALY ICER 
1860 [sitagliptin] £1,842 0.187 £9,851 £3,224 0.308 £10,465 
LEAD5 [exenatide]    £3,638 0.240 £10,054 
LEAD6 [glargine]    £1,638 0.163 £15,130 
LEAD2 [glimepiride] £3,157 0.238 £6,226 £4,860 0.245 £9,376 
LEAD1 [rosiglitazone] £2,064 0.332 £13,257 £3,730 0.398 £19,837 
 
In a clarification subsequent to submission, the manufacturer provided the additional estimates of the 
cost per QALY of liraglutide 1.8mg compared to liraglutide 1.2mg within the trials where this 
comparison was made: 
 
Table 24 ICERs for 1.8 mg versus 1.2 mg doses of liraglutide 
  ICER liraglutide 1.8mg vs 1.2mg 
LEAD2 glimepiride £249,494 
LEAD1 rosiglitazone £25,129 
1860 Sitagliptin £11,414 
 
 
Subgroup analyses: Results 
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The final NICE protocol specified possible subgroup analyses around: baseline HbA1c, 
cardiovascular risk and BMI. The economics of the submission presents the results of modelling for 
the two subgroups: 
 BMI >30kg/m2  
 BMI >35kg/m2  
for the three main comparisons undertaken: 1860 for sitagliptin, LEAD5 for exenatide and LEAD6 for 
glargine. 
 
The clinical inputs to these simulations within CORE are outlined within appendix 9 of the 
submission, with the underlying statistical analyses for LEAD-6 being reported in figures A-2 to A-6 
of appendix 5. The underlying statistical analyses for 1860 and LEAD-5 do not appear to have been 
presented within the submission.  
 
The population characteristics and clinical input parameters presented within the submission for these 
subgroups have not been cross checked by the ERG. The CORE model inputs for these subgroup 
analyses have similarly not been cross checked by the ERG. For ease of reference a summary of the 
results of this subgroup modelling is presented below:  
 
Table 25 Results of BMI subgroup modelling 
 Liraglutide 1.2mg vs comparator Liraglutide 1.8mg vs comparator 
 Δ£ ΔQALY ICER Δ£ ΔQALY ICER 
1860 [sitagliptin] £1,842 0.187 £9,851 £3,224 0.308 £10,465 
 BMI > 30kg/m
2
  £1,793 0.236 £7,593 3,225 0.370 £8,721 
 BMI > 35kg/m
2
   £1,856 0.303 £6,125 2,977 0.489 £6,091 
LEAD5 [exenatide]    £3,638 0.240 £10,054 
  BMI >30kg/m
2
     £1,650 0.143 £11,535 
  BMI >35kg/m
2
      £1,593 0.186 £8,555 
LEAD6 [glargine]    £1,638 0.163 £15,130 
  BMI >30kg/m
2
     £3,124 0.259 £12,053 
  BMI >35kg/m
2
      £2,750 0.298 £9,241 
 
Note that within the result for these subgroup analyses, the anticipated survival for those of a higher 
BMI was typically greater than that for those of a lower BMI. The manufacturer has clarified that this 
is due to the patient population with the higher BMI typically being younger at baseline, as would be 
expected due to a higher BMI leading to an earlier onset of type 2 diabetes. This earlier onset of 
diabetes more than outweighs the longer anticipated survival, and the modelling results in those of a 
higher BMI having a lower anticipated overall longevity. 
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Note also that the cost effectivenesses for the subgroups of BMI >30kg/m
2
  and BMI >35kg/m
2
  were 
typically anticipated to be better than that for the patient group as a whole. This in turn implies that 
the anticipated cost effectiveness in the subgroup with BMI < 30kg/m
2
 would be correspondingly 
worse. This would appear to apply with particular force to the LEAD-5 comparison with glargine for 
which, based upon the figure A-2 of the submission, had the patient distribution: 
 BMI ≤ 30kg/m2   50% 
 30kg/m2 < BMI ≤ 35kg/m2  31% 
 35kg/m2 < BMI   19% 
The extent to which the cost effectiveness for those with BMI ≤ 30kg/m2 worsen compared to the base 
case was unfortunately not presented within the submission. 
 
4.5 Sensitivity analyses within the submission 
 
The manufacturer undertook a range of univariate sensitivity analyses within the submission: 
1. discount rates were varied between 0.0% and 6.0%, with an additional sensitivity analysis of 
the old NICE discount rates of 1.5% for benefits and 6.0% for costs being applied 
2. an arbitrary variation of the costs of complications  by ±20% 
3. treatment durations of 3 years, 8 years and lifetime 
4. applying the CG87 disutility for BMI changes, and only applying the direct disutility from 
BMI changes to the initial treatment 
5. applying a disutility of -0.0052 to all hypoglycaemic events, and applying no disutility to 
hypoglycaemic events 
6. an arbitrary variation of the clinical effects by +10% for one arm and -10% for the other 
7. applying results to the population characteristics of the CG87 cohort 
8. equalising effects upon HbA1c 
9. equalising effects on SBP 
10. varying the time horizon to 10 years and to 20 years 
 
These are summarised below for ease of reference. 
Table 26 Manufacturer univariate sensitivity analyses: All patients 
  1860 LEAD5 LEAD6 
  1.2mg 1.8mg 1.8mg 1.8mg 
Basecase ICERS £9,851 £10,465 £15,130 £10,054 
Discount rates         
1a discount rates 0% £6,720 £6,876 £10,436 £6,595 
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1b discount rates 6% £12,452 £13,562 £18,922 £13,093 
1c discount rates NICE old £7,234 £7,572 £10,980 £7,139 
Complication costs        
2a Complication costs -20% £10,080 £10,865 £15,198 £10,603 
2b Complication costs +20% £9,623 £10,065 £15,061 £9,503 
Treatment duration         
3a Initial treatment 3 years £4,321 £4,748 £8,476 £4,741 
3b Initial treatment 8 years £16,497 £17,994 £24,491 £16,840 
3c Initial treatment lifetime £36,659 £40,624 £45,324 £31,690 
Weight effects        
4a CG87 disutility £11,637 £11,788 £17,774 £10,171 
4b Only initial treatment £13,752 £13,461 £18,984 £10,826 
Hypoglycaemia disutilities         
5a All -0.0052 £9,852 £10,552 £14,825 £9,870 
5b All no disutility £9,686 £10,298 £14,732 £10,864 
Clinical effectiveness        
6a Liraglutide 20% relative improvement £5,614 £7,238 £11,700 £5,737 
6b Comparator 20% relative improvement £18,361 £15,914 £21,118 £27,290 
Cohort         
7a CG87 cohort £11,526 £10,757 £12,526 £10,270 
Equalisation of single clinical variable        
8 HbA1c £21,018 £25,926 £22,735 £28,391 
9 SBP £9,724 £10,491 £18,764 £9,946 
Time horizon         
10a 10 years £21,687 £27,879 £34,895 £27,203 
10b 20 years £11,467 £12,628 £18,381 £12,628 
 
The alternative assumptions as to the direct disutility from BMI increases and their application after 
the change from initial therapy to glargine were also performed for the BMI subgroups. 
 
Table 27 Manufacturer univariate sensitivity analyses: BMI >30kg/m
2
  
  1860   LEAD5 LEAD6 
 1.2mg 1.8mg 1.8mg 1.8mg 
Basecase £7,593 £8,721 £12,053 £11,535 
Weight effects         
4a CG87 disutility £8,597 £9,705 £13,959 £12,205 
4b Only initial treatment £10,064 £11,196 £15,364 £13,586 
 
Table 28 Manufacturer univariate sensitivity analyses: BMI >35kg/m
2
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  1860   LEAD5 LEAD6 
 1.2mg 1.8mg 1.8mg 1.8mg 
Basecase £6,125 £6,091 £9,241 £8,555 
Weight effects         
4a CG87 disutility £6,964 £6,583 £10,978 £8,603 
4b Only initial treatment £8,434 £7,665 £12,770 £9,620 
 
4.6 ERG Additional sensitivity analyses 
 
Impact of individual clinical effects 
In order to better understand the impact of the individual clinical effects, the ERG implemented the 
individual clinical effects observed within the trials to quantify the main contributors to the 
anticipated patients outcomes and costs for the five trials of the submission.  
 
The tables below summarise these impacts on the net changes for the three main trials: 1860, LEAD-5 
and LEAD-6. Within this, the first row is the base case of the submission. Subsequent rows relate to 
the sensitivity analyses of: 
 SA1 Only the direct drug costs with no clinical effect, simply as a baseline for comparison 
 SA2a Applying the change in BMI but not applying any direct disutility from weight 
changes 
 SA2a Applying the change in BMI and applying any direct disutility from weight changes 
 SA3 Applying the changes in cholesterol and triglycerides 
 SA4 Applying the changes in systolic blood pressure 
 SA5 Applying the changes in HbA1c 
 
Note that in addition to the clinical effects, SA2a through to SA5 also apply the changes in the direct 
drug costs of SA1. Note also that for SA1 through to SA5 the rates of hypos were set to zero in order 
to identify the individual clinical effects of the changes. The treatment-specific individual clinical 
changes were applied to each arm of the trial modelled; e.g. for SA5 of LEAD-5 an HbA1c drop of 
1.33% for liraglutide 1.8mg and of 1.09% for glargine. (Note that these are not placebo-corrected, but 
the difference does not change). 
 
The tables below show the base case results, and how these differ from SA1 of no clinical effects and 
only the direct drug costs being applied. Thereafter, the results of the various sensitivity analyses are 
presented, coupled with the percentage contribution the clinical variable in question makes to the 
difference between there being no clinical effects as per SA1 and there being all the clinical effects 
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simultaneously as per the basecase. These percentages are mainly of relevance to the assessment of 
the contribution of individual clinical effects to the patient outcomes of life expectancy and QALYs. 
The individual effects will typically not sum to 100% of the overall clinical effect due sub-models 
within CORE not being independent. 
 
Table 29 Results of ERG sensitivity analyses: liraglutide 1.2 versus sitagliptin 
1860  Net Effect  
Lira 1.2mg vs Sita 100mg Life expectancy QALYs (disc) Treatment Costs Total Costs  
Basecase   **** **** **** **** ****** *** ****** ***** 
SA1 Only direct drug costs **** * **** * ****** * ****** * 
SA2a Weight: no direct utility  **** ** **** ** ****** ** ****** **** 
SA2b Weight: direct utility  **** ** **** *** ****** ** ****** **** 
SA3 Chol & triglycerides ***** *** ***** *** ****** *** ****** *** 
SA4 SBP **** *** **** *** ****** *** ****** *** 
SA5 HbA1c **** *** **** *** ****** *** ****** **** 
SA2b-5   * *** * ***      
 
The above indicates that while weight changes had a minor impact upon the anticipated gain in life 
expectancy, this was largely offset by the changes in cholesterol, triglycerides and SBP. 
**********************************************************************************
**********************************************************************************
**********************************************************************************
************************************************************** 
**************
*
**************************************
*
****************. The 
contribution of changes in BMI to the anticipated QALY gain is overwhelmingly due to the direct 
utility effects assumed, and is not due to any differences in the downstream complications of diabetes 
that result. 
 
Table 30 ERG sensitivity analyses: liraglutide 1.8mg versus sitagliptin  
1860  Net Effect  
Lira 1.8mg vs Sita 100mg Life expectancy QALYs (disc) Treatment Costs Total Costs  
Basecase   **** **** **** **** ****** **** ****** ***** 
SA1 Only direct drug costs **** * **** * ****** * ****** * 
SA2a Weight: no direct utility  **** ** **** ** ****** ** ****** *** 
SA2b Weight: direct utility  **** ** **** *** ****** ** ****** *** 
SA3 Chol & triglycerides **** *** **** ** ****** *** ****** *** 
SA4 SBP **** ** **** *** ****** *** ****** *** 
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SA5 HbA1c **** *** **** *** ****** *** ****** **** 
SA2b-5   * *** * ***      
 
**********************************************************************************
**********************************************************************************
**********************************************************************************
**********************************************************************************
*************************************************************
*
********************
******************
*
***************** 
 
Table 31 ERG sensitivity analyses: liraglutide versus glargine. 
LEAD-5  Net Effect  
Liraglutide 1.8mg vs glargine Life expectancy QALYs (disc) Treatment Costs Total Costs  
Basecase   0.17 0.17 0.24 0.24 £3,720 £121 £3,638 £39 
SA1 Only direct drug costs 0.00   0.00   £3,599   £3,599   
SA2a Weight: no direct utility  0.02 12% 0.02 7% £3,611 10% £3,639 103% 
SA2b Weight: direct utility  0.02 12% 0.11 48% £3,613 12% £3,641 108% 
SA3 Chol & triglycerides 0.02 14% 0.02 8% £3,614 12% £3,535 -164% 
SA4 SBP 0.08 45% 0.07 28% £3,648 40% £3,527 -185% 
SA5 HbA1c 0.04 25% 0.04 18% £3,630 26% £3,447 -390% 
SA2b-5     96%   102%      
 
In contrast to 1860, given the similar clinical profiles of liraglutide 1.8 mg and glargine in LEAD-5 
the principal source of the additional life expectancy for liraglutide 1.8 mg arises from the changes in 
SBP: -3.97mmHg for liraglutide 1.8 mg as compared to +0.54 mmHg for glargine. HbA1c has 
relatively little impact given changes of -1.33% and -1.09% for liraglutide 1.8 mg and glargine 
respectively. Turning to the QALY side of the equation, the single largest contributor to this appears 
to be the direct utility impact from changes in BMI: -0.644kg/m
2
 for liraglutide 1.8mg as compared to 
+0.577kg/m
2
 for glargine. 
 
Table 32 ERG sensitivity analyses: liraglutide versus exenatide 
LEAD6  Net Effect : Liraglutide 1.8mg minus exenatide 10μg 
Liraglutide 1.8mg vs exenatide 10μg Life expectancy QALYs (disc) Treatment Costs Total Costs  
Basecase   0.15 0.15 0.16 0.16 £2,085 £98 £1,638 -£349 
SA1 Only direct drug costs 0.00   0.00   £1,987   £1,987   
SA2a Weight: no direct utility  0.00 1% 0.00 1% £1,988 1% £1,981 2% 
SA2b Weight: direct utility  0.00 1% 0.02 11% £1,988 1% £1,981 2% 
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SA3 Chol & triglycerides 0.04 28% 0.03 20% £2,014 28% £2,007 -6% 
SA4 SBP 0.00 1% 0.00 2% £1,989 2% £1,944 12% 
SA5 HbA1c 0.08 54% 0.09 56% £2,041 55% £1,651 96% 
SA2b-5     84%   90%      
 
Among the three main comparisons, LEAD-6 is the exception. With both liraglutide and exenatide 
being GLP-1s there is minimal difference between them in terms of BMI changes: -1.145kg/m
2
 for 
liraglutide 1.8 mg as compared to -1.015kg/m
2
 for exenatide. The main source of patient benefits both 
in terms of life expectancy and QALYs is the superior HbA1c profile for liraglutide 1.8 mg of -1.12% 
as compared to -0.79% for exenatide, coupled with some additional superiority in cholesterol and 
triglycerides. Within this, it should be borne in mind that the anticipated patient gain in LEAD-6 is the 
smallest of the three main comparisons. 
 
Weight direct utility effects 
The previous section highlighted the importance of the effects of weight changes upon the modelling 
undertaken by the manufacturer. Appendix 11 of the manufacturer submission outlined the calculation 
of the disutilities applied within the modelling. More transparently, for the three main comparisons 
undertaken, the effects of the direct disutilities from weight changes can be summarised as below, and 
as outlined in greater detail in Appendix 6. The column “excess BMI 25+” refers to the difference 
between mean BMI in the trial groups and the upper normal limit of BMI, taken to be 25. 
 
Table 33 ERG sensitivity analyses: application of weight disutilities 
 From  To Excess Annual Annual 
 BMI ΔBMI BMI BMI25+ Disutility Net 
1860 Sitagliptin       
1st line year 1-5       
Liraglutide 1.2 **** ** **** *** ****** ***** 
Liraglutide 1.8 **** ***** ***** **** ****** ***** 
Sitagliptin **** ***** ***** **** ******  
2nd line year 6+       
Liraglutide 1.2 **** ***** ****** ***** ****** ***** 
Liraglutide 1.8 ***** ***** ****** ***** ****** ***** 
Sitagliptin ***** ***** ****** ***** *****  
LEAD-5 Glargine       
1st line year 1-5       
Liraglutide 1.8 30.5 -0.644 29.856 4.856 -0.049 0.012 
Glargine 30.5 0.577 31.077 6.077 -0.061  
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2nd line year 6+       
Liraglutide 1.8 29.856 0.577 30.433 5.433 -0.054 0.006 
Glargine 31.077 0 31.077 6.077 -0.061  
LEAD-6 
Exenatide       
1st line year 1-5       
Liraglutide 1.8 32.95 -1.145 31.805 6.805 -0.068 0.001 
Exenatide 32.95 -1.015 31.935 6.935 -0.069  
2nd line year 6+       
Liraglutide 1.8 31.805 0.577 32.382 7.382 -0.074 0.001 
Exenatide 31.935 0.577 32.512 7.512 -0.075  
 
The key point in the above is that the net annual impact during the initial 5 year treatment is assumed 
to carry over to the remainder of the modelling. Movement on to glargine is associated with the same 
step change in BMI for both arms, resulting in patients being anticipated to maintain the weight 
changes of the first year for the time horizon of the modelling. 
 
This also applies within the modelling of LEAD-5 comparing liraglutide 1.8 mg with glargine, but 
with the slight difference that there is no move to a different third line drug for the glargine arm. 
Despite patients in both arms being on glargine for years 6+, during this period of the modelling those 
in the liraglutide arm are still anticipated to be of lower weight than those in the glargine arm. 
 
As can also be seen from the above the anticipated net impact within the comparison with the other 
GLP-1, exenatide, is very small. 
 
As a cross check and relatively simple ready-reckoner for predicting the effects of changes to the 
assumptions around the direct utility gains from weight changes, the annual disutilities can be applied 
to the approximate average survival of 16 years to provide an estimate of the discounted gains as a 
percentage of the total QALY gain of the base case modelling: 
 during  treatment in years 1-5,  
 during later treatment of years 6+ 
 over the period of the modelling 
 
Table 34 Estimate of percentage of QALY gain resulting from weight disutilities 
 1860 LEAD5 LEAD6 LEAD1 LEAD2 
 1.2mg 1.8mg 1.8mg 1.8mg 1.2mg 1.8mg 1.2mg 1.8mg 
 year 1-5 *** *** 24% 4% 9% 10% 24% 25% 
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 year 6-16 *** *** 21% 6% 15% 17% 41% 42% 
Total year 1-16 *** *** 45% 10% 25% 27% 65% 67% 
 
Changes to the assumptions around the size of the utility decrement per BMI point from the base case 
value of -0.01 would have a proportionate effect on the above. For instance, a decrement of only -
0.005 would reduce the QALY gain from liraglutide in LEAD-6 by approximately 5% with a parallel 
effect on the ICER, while the QALY gain from liraglutide in LEAD-5 would be reduced by 
approximately 22% again with a parallel effect on the ICER. The totals for years 1-16 show a 
reasonable correspondence with the figures suggested by the sensitivity analyses 2a and 2b for trials 
1860, LEAD-5 and LEAD-6 as reported in the previous section. 
 
The manufacturer undertook sensitivity analyses that applied the CODE-2 disutility of -0.0061 per 
BMI point as per CG87, a reduction of 40%: 
 
Table 35 Manufacturer’s sensitivity analyses using CODE-2 weight disutilities 
 1860 LEAD5 LEAD6 LEAD1 LEAD2 
 1.2mg 1.8mg 1.8mg 1.8mg 1.2mg 1.8mg 1.2mg 1.8mg 
Basecase ****** ******* £15,130 £10,054 £6,226 £9,376 £13,257 £19,837 
  Revised ******* ******* £17,774 £10,171 £6,768 £10,280 £17,318 £26,244 
  % change *** *** 17% 1% 9% 10% 31% 32% 
  % change / 40% *** *** 44% 3% 22% 24% 77% 81% 
 
Within this, the % change / 40% shows reasonable agreement with the total year 1-16 percentages of 
the ready-reckoner, with the exception of the results for LEAD-2.  
 
Similarly, if the direct disutility effects from weight changes are restricted to only the initial treatment 
the anticipated QALY gains would be reduced by the post-5-year treatment effects. The manufacturer 
undertook this set of analyses for the base case disutility of -0.01 per BMI point, resulting in the 
ICERs: 
 
Table 36  Manufacturer’s sensitivity analyses: disutilities from weight changes 
 1860 LEAD5 LEAD6 LEAD1 LEAD2 
 1.2mg 1.8mg 1.8mg 1.8mg 1.2mg 1.8mg 1.2mg 1.8mg 
Basecase ****** ******* £15,130 £10,054 £6,226 £9,376 £13,257 £19,837 
  Revised ******* ******* £18,948 £10,826 £7,402 £11,352 £22,088 £33,730 
  % change *** *** 25% 8% 19% 21% 67% 70% 
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**********************************************************************************
**********************************************************************************
*************************************************************** As for the change in 
the utility decrement, there is also relatively poor correspondence for the LEAD-2 results between the 
sensitivity analysis of the manufacturer that removes any differential weight gain between the arms 
for the 2
nd
 line treatment and the ready-reckonner. Whether the reason for these discrepancies is a 
misinterpretation or error by the ERG is currently unclear, and unfortunately deadlines have precluded 
the ERG from formally running these simulations within CORE.  
 
Direct treatment costs 
As outlined in the section cross checking the direct drug costs, three additional sensitivity analyses 
around these were undertaken by the ERG: 
 for LEAD-6 assuming one needle per day for both liraglutide and exenatide 
 for LEAD-5 assuming a glargine dose of 24IU throughout 
 for LEAD-5 assuming NPH was used rather than glargine, with a similar dose  
 
One needle per day for exenatide: 
One needle per day for both liraglutide and exenatide reduces the anticipated treatment costs for 
exenatide by around 5%. This saw the estimated direct treatment cost in the exenatide arm fall from 
£8,878 to £8,700, this direct treatment cost being the discounted total of both initial exenatide and 
subsequent glargine. Given this relatively minor change, the estimate cost effectiveness worsened 
only slightly from £10,054 per QALY in the base case to £11,079 per QALY if exenatide only 
requires one needle per day. 
 
24 IU glargine dose: 
Assuming a glargine dose of 24 IU daily through the modelling reduced the direct treatment costs for 
both the liraglutide 1.8 mg arm and the glargine arm. For the former these fell from £11,090 to 
£9,793, while for the latter a steeper decline was seen of £7,370 to £5,673. This caused the estimated 
cost effectiveness of liraglutide 1.8mg to worsen from £15,130 per QALY to £16,793 per QALY. 
 
Table 37 Sensitivity analysis: glargine dose 24 units daily throughout 
 Liraglutide 1.8mg Glargine Net 
Direct Treatment Costs £9,793 £5,673 £4,120 
Other Costs £14,019 £14,101 -£82 
Total Costs £23,812 £19,774 £4,038 
QALYs 7.30 7.06 0.24 
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ICER   £16,793 
 
Note that a similar sensitivity analysis was performed by the manufacturer in section 7.5.3.1 of the 
submission, with the results reported in table 45 [p91]. In this the manufacturer estimated that the cost 
effectiveness of liraglutide would worsen to £22,188 per QALY. This result appears to have arisen 
due to the manufacturer assuming a dose of 24 IU for the glargine arm for the period of the modelling, 
but retaining a dose of 40IU for 2
nd
 line glargine for the liraglutide 1.8 mg arm. If the base case direct 
treatment costs of the liraglutide 1.8 mg arm are substituted into this analysis it results in: 
 
Table 38 Sensitivity analysis - glargine doses and costs 
 Liraglutide 1.8mg Glargine Net 
Direct Treatment Costs £11,090 £5,673 £5,417 
Other Costs £14,019 £14,101 -£82 
Total Costs £25,109 £19,774 £5,335 
QALYs 7.30 7.06 0.24 
ICER   £22,229 
which broadly tallies with the £22,188 per QALY result of the manufacturer sensitivity analysis. 
 
NPH instead of glargine: 
Assuming that NPH was used at a dose of 24IU in the 1
st
 year and 40 IU thereafter reduced the direct 
treatment costs for both the liraglutide 1.8 mg arm and the glargine arm, the reduction in the 
liraglutide 1.8mg arm again being due to the progression to 2
nd
 line insulin at year 5. The direct 
treatment costs for liraglutide 1.8mg fell from £11,090 to £9,360, while for the insulin arm a steeper 
decline was seen of £7,370 to £5,013. This caused the estimated cost effectiveness of liraglutide 
1.8mg to worsen from £15,130 per QALY to £17,739 per QALY. 
 
Table 39 Sensitivity analysis using NPH instead of glargine 
 Liraglutide 1.8mg NPH Net 
Direct Treatment Costs £9,360 £5,013 £4,347 
Other Costs £14,020 £14,101 -£82 
Total Costs £23,380 £19,114 £4,265 
QALYs 7.30 7.06 0.24 
ICER   £17,739 
 
Note that a similar sensitivity analysis was also performed by the manufacturer in section 7.5.3.1 of 
the submission, with the results again reported in table 45 [p91]. In this the manufacturer estimated 
that the cost effectiveness of liraglutide would worsen to £24,933 per QALY. This result appears to 
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have arisen due to the manufacturer assuming that NPH was used for the comparator arm, but that 
within the 1.8mg liraglutide arm the insulin at year 5 would be 40IU glargine. If the base case direct 
treatment costs of the liraglutide 1.8mg arm are substituted into this analysis it results in: 
 
Table 40 Sensitivity analysis with NPH – Liraglutide base case substitution 
 Liraglutide 1.8mg NPH Net 
Direct Treatment Costs £11,090 £5,013 £6,077 
Other Costs £14,020 £14,101 -£81 
Total Costs £25,110 £19,114 £5,996 
QALYs 7.30 7.06 0.24 
ICER   £24,983 
which broadly tallies with the £24,933 per QALY result of the manufacturer sensitivity analysis. 
 
4.7 Post submission additional manufacturer sensitivity analyses: Indexation 
For the base case the costs of the complications of diabetes were taken in large part from Clarke and 
Colleagues (2003)
50
 with this being uplifted for inflation using the HSCI index. Given that these costs 
were in 1999 prices, this resulted in a 12% uplift to result in 2008 prices. While there may be some 
concerns around indexing costs over such a long period, as outlined in greater detail in Appendix 5, it 
would seem more appropriate to have applied the HCHS index which would have resulted in a 42% 
uplift. 
 
Such a change might appear dramatic given that the costs of complications typically exceeded the 
direct costs of treatment. But it should be borne in mind that the rates of complications and the costs 
associated with them were similar between arms, and the net effects were correspondingly reduced. 
While a net cost offset was provided by a reduction in the costs of complications from the more 
effective treatment, the effect of applying the HCHS index is a relatively minor increase in this net 
cost offset.  
 
The manufacturer has provided an additional set of analyses that performs this comparison with the 
estimates of the cost per QALY of this reported below, where the HSCI values are the base case 
estimates: 
 
Table 41 Effect of indexation on ICERs 
 1.2mg liraglutide versus comparator 1.8mg liraglutide versus comparator 
Indexation HSCI HCHS HSCI HCHS 
1860      [sitagliptin] £9,851 £9,541 £10,465 £9,879 
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LEAD5 [glargine]   £15,130 £15,103 
LEAD6 [exenatide]   £10,054 £9,212 
LEAD1 [rosiglitazone] £6,226 £5,544 £9,376 £8,748 
LEAD2 [glimepiride] £13,257 £13,155 £19,837 £19,729 
 
 
4.8 Comparison of submission with NICE reference case 
Table 42 NICE reference case checklist 
 
Attribute Reference case Does the de novo economic 
evaluation match the 
reference case 
Comparator(s)  Therapies routinely used in the 
NHS, including technologies 
regarded as current best practice  
Yes 
Perspective costs NHS and Personal Social 
Services (PSS)  
NHS perspective only. The 
manufacturer has justified the 
absence of PSS costs (page 48). 
Perspective benefits  All health effects on individuals All important effects are 
included in the CORE model. 
Some disutilities are not 
included, such as injection 
discomfort and nausea, but 
these are unlikely to have 
significant effect. 
Form of economic evaluation  Cost-effectiveness analysis  Yes 
Time horizon Sufficient to capture differences 
in costs and outcomes  
Yes – 40 year horizon 
Synthesis of evidence on 
outcomes  
Systematic review Yes 
Outcome measure  Quality adjusted life years 
(QALYs)  
Yes 
Health states for QALY  Described using a standardised 
and validated instrument  
Yes, derived from a series of 
published studies and 
incorporated in CORE. Most 
utilities were based on EQ5D. 
Benefit valuation  Time-trade off or standard 
gamble  
The majority of utilities were 
drawn from the Clarke et al 
2002 UKPDS paper which 
relied on the tobit modelling of 
EQ-5D tariff values.
50
 
Source of preference data for 
valuation of changes in HRQL  
Representative sample of the 
public  
Utilities were taken mainly 
from the UKPDS, a very large 
study in the UK. 
Discount rate  An annual rate of 3.5% on both 
costs and health effects  
Benefits and costs, where 
appropriate, have been 
discounted using the 3.5% rate  
Equity  An additional QALY has the 
same weight regardless of the 
All QALYs estimated by the 
economic model have the same 
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other characteristics of the 
individuals receiving the health 
benefit  
weight. 
Sensitivity analysis  Probabilistic sensitivity analysis 
(PSA)  
PSA was undertaken by the 
manufacturer for the base case.   
 
This was also coupled with a 
range of univariate sensitivity 
analyses, with these univariate 
sensitivity analyses being 
implemented within the 
probabilistic CORE model 
structure. 
 
 
 
Item  Critical 
appraisal  
ERG comment  
Was a well-defined 
question posed in 
answerable form?  
Yes  Three main comparisons were performed: 
 liraglutide 1.2mg and 1.8mg with  sitagliptin  
100mg, both arms in conjunction with metformin, 
based upon study 1860; 
 liraglutide 1.8mg with exenatide 10μg, both arms in 
conjunction with metformin and/or sulphonylurea, 
based upon study LEAD-6 
 liraglutide 1.8mg with glargine , both arms in 
conjunction with metformin and sulphonylurea, based 
upon study LEAD-5 
Coupled with two additional comparisons for 
completeness, given the clinical evidence base: 
 liraglutide 1.2mg and 1.8mg with  rosiglitazone  4mg, 
both arms in conjunction with sulphonylurea, based 
upon study LEAD-1; 
 liraglutide 1.2mg and 1.8mg with  glimepiride  4mg, 
both arms in conjunction with metformin, based upon 
study LEAD-2; 
The viewpoint of the analysis was as specified for the NICE 
reference case. 
Was a comprehensive 
description of the 
competing alternatives 
given?  
Yes  This was largely defined within the NICE protocol and 
interpreted above in the light of head to head trial data being 
available. 
Was the effectiveness 
of the intervention 
established?  
Yes  The clinical effectiveness of liraglutide was well established 
and is not in doubt. 
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Were all the important 
and relevant costs and 
consequences for each 
alternative identified?  
Yes, as far as 
is possible 
with current 
data. 
The studies of the GLP-1 agonists are of quite short 
duration (up to two years in open extension studies) and it is 
not possible to be sure that there will be no long term 
adverse effects such as pancreatitis or thyroid cancer with 
liraglutide. The evidence for a link between exenatide and 
pancreatitis is growing but it seems to be quite a rare 
occurrence. There is now also concern about renal failure 
with exenatide, but the link may not be causal. (FDA 
website).
59
 
 
Nausea was not considered within the economic modelling, 
but this would be of relatively short duration and for those 
remaining on treatment probably have limited impact upon 
quality of life. Modelling could have considered nausea as 
affecting the probability of discontinuing but the clinical 
effectiveness data does not suggest serious differences in 
discontinuation rates between the arms of the head to head 
trials. 
 
Alternative viewpoints, such as a societal viewpoint for 
benefits, were not explored. Given the license and position 
sought for liraglutide it seems likely that alternative 
viewpoints would not have particularly affected the 
analysis. Loss of earnings and productivity may apply with 
disease progression. Similarly, there may be additional third 
party carer considerations as disease progresses. These 
seem unlikely to differ substantially between arms. 
Were costs and 
consequences 
measured accurately in 
appropriate physical 
units?  
Yes The physical units of the costs and consequences were 
largely outputs of the CORE model. 
Were the cost and 
consequences valued 
credibly?  
Yes The manufacturer used the well-developed CORE model 
which includes costs. In the main these appears to have 
been credibly valued. There were some gaps and there may 
have been some double counting of some outpatient costs, 
but the overall impact of this seems unlikely in itself to have 
a significant effect upon results. 
 
The consequences (most notably the complications of 
diabetes) were estimated in the model based on HbA1c, the 
standard measure of glycaemic control, which correlates 
well with most complications. Blood pressure and weight 
were also used in the modelling to predict future health 
effects. 
Were costs and 
consequences adjusted 
for differential timing?  
Yes  The costs of complications as taken from UKPDS 65 were 
uprated for inflation to 2008 prices using the Health 
Services Cost Index (HSCI), for goods and services 
purchased, as reported in the PSSRU Unit Costs of Health 
and Social Care. With UKPDS 65 being in 1999 prices this 
led to a 12% uplift in the nominal costs of complications. 
The manufacturer could have argued for applying the 
Hospital and Community Health Services (HCHS) index, 
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this being the aggregate effect of pay inflation as measured 
by the Pay Cost Index (PCI) and the HSCI. This would have 
seen a 42% uplift in the nominal costs of complications. 
The effects of applying the HCHS index have been explored 
through additional analyses supplied by the manufacturer 
and are reported below. The reasonableness of uprating 
costs from 1999 to 2008 values may be called into question, 
but UKPDS 65 remains a reasonably standard reference. It 
also has the additional benefit of being a coherent source 
across the variety of complications associated with diabetes 
that is independent of both the CORE modelling and the 
manufacturer. 
Was an incremental 
analysis of costs and 
consequences of 
alternatives 
performed?  
Yes  Yes 
Was allowance made 
for uncertainty in the 
estimates of costs and 
consequences?  
Yes  Yes, the CORE model is by nature a probabilistic model 
and the uncertainty surrounding the estimates of clinical 
effectiveness was applied throughout the modelling. The 
submission reported the CEAC probabilities for willingness 
to pay values of £20k per QALY and £30k per QALY. 
Did the presentation 
and discussion of study 
results include all 
issues of concern to 
users?  
Yes  
 
ERG= Evidence Review Group; cancer; QALY=quality adjusted life year; LYG=life year gained; 
SA=sensitivity analysis; PSA=probabilistic sensitivity analysis; ICER=incremental cost-effectiveness 
ratio.  
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5. DISCUSSION 
5.1 Summary of clinical effectiveness 
 
Novo Nordisk provided a good submission which listed a large number of trials but which then 
focused on the most relevant ones, which came from an integrated series of trials, known as the 
LEAD ones, which tested liraglutide at the various stages in the progression of type 2 diabetes. All the 
studies have been sponsored by the manufacturer  
 
We started from the position that UK practice would be as recommended in the NICE guideline, with 
GLP-1 agonists being used as third drug after dual therapy with two of metformin, a sulphonylurea 
and a glitazone being used. The comparators for liraglutide would therefore be a basal insulin, 
exenatide or one of the other new class of drugs, the DPP-4 inhibitors such as sitagliptin or 
vildagliptin. 
 
We therefore paid most attention to the studies which compared liraglutide, namely LEAD-5, LEAD- 
6 and the unpublished 1860.  However we also reviewed trials in which liraglutide was used as the 
second drug, for example in combination with metformin, in case NICE decided to recommend such 
use. 
 
Our conclusion was that liraglutide was clinically effective in both doses used, 1.2 mg and 1.8 mg. 
Like others in this class of drugs, it has advantages over most other oral glucose lowering agents, in 
that its action is glucose dependent so that it does not cause hypoglycaemia.  It shares this 
characteristic with the gliptins, which also act on the incretin system. The other characteristic of the 
GLP-1 agonists is weight loss. With the exception of the gliptins, which tend to be weight-neutral, 
other second or third line drugs, the sulphonylureas, the glitazones and insulin, cause weight gain. 
 
Because of the significant cost difference, we examined the relative benefits of the 1.8 mg dose over 
the 1.2 mg dose, and concluded that in most patients, the differences were small and that 1.2 mg 
would suffice. This is the expectation of Novo Nordisk (page 11 of the industry submission). 
 
It has been suggested that patients with the highest BMIs might benefit more from the higher dose, 
and in trial 1860, 
**********************************************************************************
**********************************************************************************
Copyright 2010 Queen's Printer and Controller of HMSO. All rights reserved.
72 
 
**********************************************************************************
****** 
 
Weaknesses in evidence 
The main weakness is that the trials were of short duration, and we cannot at present be sure of the 
long-term safety. Exenatide appeared safe in the trials, but concerns are growing over pancreatitis, and 
more recently, renal failure. 
45,46,59
 If pancreatitis is a real, if rare, consequence of exenatide, will that 
be limited to exenatide or a class effect? There have been past occasions where only one of a class of 
drugs had specific adverse effects, such as sclerosing peritonitis with practolol, or liver problems with 
troglitazone. 
 
Another weakness is a common one in diabetes trials, that no data on long-term complications are 
available. However given the timescale of complications such as retinopathy or cardiovascular 
disease, it would be unrealistic to expect such data from trials, and modelling based on intermediate 
indicators such as glycaemic control as reflected in HbA1c is usually accepted as a reliable prediction 
of future outcomes. 
 
5.2 Summary of cost-effectiveness 
The submission used the CORE model, which is a well-developed and well-respected diabetes model. 
As the CORE model is not standard software as defined by NICE, the manufacturer confirmed with 
the NICE secretariat that its use for this submission would be acceptable. The CORE model has also 
been used for previous modelling for NICE in the assessment of continuous subcutaneous insulin 
infusion compared to multiple daily injections. 
 
The manufacturer presented three main sets of analyses, based upon the three main clinical trials 
noted above: 
 LEAD-5 comparing liraglutide 1.8mg with glargine 
 LEAD-6 comparing liraglutide 1.8mg with exenatide 
 1860 comparing liraglutide 1.2mg and 1.8mg with sitagliptin 
Initial treatments were assumed to be for 5 years in the base case, with patients then switching to 
glargine. 
 
The ERG has cross checked the parameter values used within the manufacturer modelling. Where 
parameter values were drawn from the literature, with the exception of a few parameters the cited 
references contained values that cross checked with those presented within the submission. With the 
exception of a small number of parameters, the values reported within the submission cross checked 
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with those implemented within CORE. The exceptions seem unlikely to markedly affect analyses 
given base case results.  
 
Similarly, the clinical effectiveness estimates taken from the trials and reported within the appendices 
of the submission as having been applied within CORE cross checked with those implemented within 
CORE, with only a very minor exception. 
 
Re-running the base cases within CORE saw results cross check with those reported by the 
manufacturer within the submission.  
 
We have not yet resolved uncertainties around the implementation of treatments subsequent to the 
initial treatment, in the CORE model. But the likelihood is that if resolved, this would be to the 
benefit of liraglutide. 
 
There may also be some concerns around the implementation of weight changes within the modelling. 
The duration of the direct benefits from initial treatments may have been too long, and the direct 
disutility associated with these changes may also have been too large.  
 
For the base cases the manufacturer estimated a cost effectiveness of: 
 £15,130 per QALY for liraglutide 1.8mg compared to glargine 
 £10,054 per QALY for  liraglutide 1.8mg compared to exenatide 
 £10,465 per QALY for  liraglutide 1.8mg compared to sitagliptin 
 £9,851 per QALY for  liraglutide 1.2mg compared to sitagliptin 
 
Additional sub-group analyses undertaken by the manufacturer suggested that for patients of a higher 
BMI liraglutide was typically more cost effective. The estimates of cost effectiveness for those of a 
lower BMI were not presented. 
 
Univariate sensitivity analyses undertaken by the manufacturer suggested that these estimates were 
most sensitive to: 
 the assumed duration of initial therapy 
 the application of weight changes and disutility associated with this 
 the time horizon of the analysis 
 
Additional sensitivity analyses undertaken by the ERG suggested that the main sources of the 
estimated patient benefits were: 
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 the direct utility effects of BMI changes and SBP, with some additional contribution from 
HbA1c, for the comparison with glargine 
 HbA1c, with some additional effects from cholesterol and triglycerides, for the comparison 
with exenatide 
 HbA1c and direct utility effects of BMI changes for the comparisons with sitagliptin 
 
Weaknesses in evidence 
 
Because the trials were short-term, it was necessary to model costs and outcomes far beyond the 
duration of the trials. 
 
In line with the NICE policy of only considering licensed products, we compared liraglutide with 
existing comparators, using a 40 year duration. In reality, daily liraglutide will soon be displaced by 
other GLP-1 agonists which are given weekly or fortnightly. 
 
5.3 Research needs 
 
The most important need is for data on long-term safety.  
 
The next need is for comparative trials of the new GLP-1 agonists with the current ones, with 
particular emphasis on cost-effectiveness and adverse effects. Head to head trials of the 1.2 mg dose 
against glargine and exenatide would be useful. 
 
A trial of weekly exenatide against daily liraglutide, known as DURATION-6, is planned by the 
manufacturer of exenatide.
40
 (DURATION is short for Diabetes therapy Utilization: Researching 
changes in A1c, weight and other factors Through Intervention with exenatide ONce weekly.)  
 
Another trial EUREXA (European Exenatide study) is examining longer-term (2.5 years) use of 
exenatide.
60
 
 
A third need is for studies long enough to determine whether this group of drugs have any effect on 
progression of disease. In the short term they appear to improve beta cell function, but this effect 
wears off a few weeks after the drug is stopped. It has been suggested that because of the slow 
turnover of human beta cells, that only studies lasting for several years could whether there is any 
effect on beta cell capacity.  Long term studies would also provide data on the duration of benefits 
such as weight changes. 
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Conclusion 
There is a good evidence base for the clinical effectiveness of liraglutide.  It helps improve diabetes 
control, and has the additional benefits of some weight loss in most users.  
Liraglutide appears safe but that can only be confirmed once there are long term data. 
There are some uncertainties about the cost-effectiveness because of the need for long-term modelling 
based on data from short-term trials. An important issue is that some current comparisons, for 
example between the two available GLP-1 analogues, daily liraglutide and twice daily exenatide, will 
be rendered obsolete shortly, with the arrival of longer-acting GLP-1 analogues given once a week or 
perhaps once every two weeks. 
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APPENDICES 
Appendix 1 List of Identified RCTs from Industry Submission 
Author Date  Title Reference Study type Inclusion in Cochrane 
review? 
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Data on file with NN RCT. Unpublished 1860  Excluded – unpublished  - 
data not available 
Buse J et al. 
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2009 Liraglutide once a day versus 
exenatide twice a day for type 2 
diabetes: a 26-week randomised, 
parallel-group, multinational, open-
label trial (LEAD-6). 
Lancet 2009; 
374(9683): 39–47 
RCT  (LEAD-6) Included 
Russell-Jones D 
et al. 
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2009 Liraglutide vs insulin glargine and 
placebo in combination with 
metformin and sulfonylurea therapy in 
type 2 diabetes mellitus (LEAD-5 
met+SU): a randomised controlled 
trial. 
Diabetologia 2009; 
52: 2046–2055 
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Zinman B et al. 
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2009 Efficacy and safety of the human 
glucagon-like peptide-1 analog 
liraglutide in combination with 
metformin and thiazolidinedione in 
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Met+TZD). 
Diabetes Care 2009; 
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RCT (LEAD-4) Included 
Nauck M et al.
61
  2009 Efficacy and safety comparison of 
liraglutide, glimepiride, and placebo, 
all in combination with metformin, in 
type 2 diabetes: the LEAD (liraglutide 
effect and action in diabetes)-2 study. 
Diabetes Care 2009; 
32: 84–90 
RCT (LEAD-2) Included 
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Marre M et al.
62
  2009 Liraglutide, a once-daily human GLP-
1 analogue, added to a sulphonylurea 
over 26 weeks produces greater 
improvements in glycaemic and 
weight control compared with adding 
rosiglitazone or placebo in subjects 
with Type 2 diabetes (LEAD-1 SU). 
Diabet Med 2009; 26: 
268–78 
RCT (LEAD-1) Excluded -  does not report 
the previous OHAs, so 
cannot determine what % 
of patients were tried on 
metformin first. Awaiting 
clarification from NN 
Garber A et al.
63
  2009 Liraglutide versus glimepiride 
monotherapy for type 2 diabetes 
(LEAD-3 Mono): a randomised, 52-
week, phase III, double-blind, parallel-
treatment trial. 
Lancet 2009; 
373(9662): 473–81 
RCT ( LEAD-3) Excluded -liraglutide 
monotherapy 
Seino Y et al.
64
 2008 Dose-dependent improvement in 
glycemia with once-daily liraglutide 
without hypoglycemia or weight gain: 
A double-blind, randomized, 
controlled trial in Japanese patients 
with type 2 diabetes. 
Diabetes Res Clin 
Pract 2008; 81: 
161−8 
RCT . 14 weeks.   
Compared  4 different 
doses of Liraglutide - 0.1 
mg, 0.3 mg, 0.6 mg, 0.9 mg 
against placebo. 
Excluded -liraglutide 
monotherapy 
Vilsboll T et 
al.
65
 
2008 Liraglutide, a once-daily human GLP-
1 analogue, improves pancreatic B-cell 
function and arginine-stimulated 
insulin secretion during 
hyperglycaemia in patients with Type 
2 diabetes mellitus 
Diabetic Medicine 
2008; 25: 152−6 
RCT. The study was part of 
a larger double-blind, 
placebo controlled, 
randomized trial conducted 
over 14 weeks (Vilsboll 
2007) comparing three 
doses of liraglutide (0.65, 
1.25 or 1.9 mg/day) vs. 
placebo(subcutaneous 
injections in the evening) 
[7] 
Excluded -liraglutide 
monotherapy 
Vilsboll T et 
al.
66
 
2007 Liraglutide, a long-acting human 
glucagon-like peptide-1 analog, given 
as monotherapy significantly improves 
glycemic control and lowers body 
weight without risk of hypoglycemia 
Diabetes Care 2007; 
30: 1608−10 
RCT.  Prior to trial patients 
were on diet or OHA. 
Previous oral anti-diabetes 
drug therapy discontinued. 
Patients were on 3 different 
Excluded -liraglutide 
monotherapy 
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in patients with type 2 diabetes. doses of Liraglutide - 0.65 
mg; 1.25 mg, 1.9mg 
against placebo for 14 
weeks 
Horowitz M et 
al. (sub-group 
publication of 
the above 
Vilsboll T et al. 
2007 paper)
67
 
2008 Patient reported rating of 
gastrointestinal adverse effects during 
treatment of type 2 diabetes with the 
once-daily human GLP-1 analogue, 
liraglutide. 
Diabetes Obes Metab 
2008; 10: 593–6 
sub-group publication of 
the  Vilsboll T et al. 2007  
Excluded - liraglutide 
monotherapy 
Courreges JP et 
al. (sub-group 
publication of 
the above 
Vilsboll T et al. 
2007 paper)
68
 
2008 Beneficial effects of once-daily 
liraglutide, a human glucagon-like 
peptide-1 analogue, on cardiovascular 
risk biomarkers in patients with Type 2 
diabetes. 
Diabet Med 2008; 25: 
1129–31 
sub-group publication of 
the  Vilsboll T et al. 2007  
Excluded - liraglutide 
monotherapy 
Nauck M et al.
69
 2006 Five weeks of treatment with the 
GLP−1 analogue liraglutide improves 
glycaemic control and lowers body 
weight in subjects with type 2 
diabetes. 
Exp Clinl Endocrino 
and Diabetes, 2006; 
114: 417−23  
RCT.  5 weeks. 144 type 2 
diabetic subjects on 
metformin treatment (1000 
mg BID) were randomised 
to 5 weeks of treatment 
(double-blind) with 
metformin plus liraglutide, 
liraglutide or metformin, or 
metformin plus glimepiride 
(open label). The dose of 
liraglutide was increased 
weekly from 0.5 to 2 mg 
OD. 
Excluded –  
5 weeks duration 
Feinglos M et 
al.
70
 
2005 Effects of liraglutide (NN2211), a 
long−acting GLP−1 analogue, on 
glycaemic control and bodyweight in 
subjects with Type 2 diabetes. 
Diabetic Medicine 
2005; 22: 1016−23 
RCT.  12 weeks.   5 
different doses of 
Liraglutide 0.045 mg, 
0.225 mg,0.45 mg; 0.6 mg;  
0.75 mg versus metformin 
Excluded - liraglutide 
monotherapy 
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+ placebo injection. 
Harder H et al.
71
 2004 The effect of liraglutide, a long−acting 
glucagon−like peptide 1 derivative, on 
glycemic control, body composition, 
and 24−h energy expenditure in 
patients with type 2 diabetes. 
Diabetes Care 2004; 
27: 1915−21 
RCT. Patients randomized 
to treatment with a single 
daily subcutaneous dose of 
0.6 mg = 21) of liraglutide 
(n = 21) or placebo (n = 
12) for 8 weeks 
Excluded - liraglutide 
monotherapy and 8 weeks 
duration 
Madsbad S et 
al.
72
 
2004 Improved glycemic control with no 
weight increase in patients with type 2 
diabetes after once−daily treatment 
with the long−acting glucagon−like 
peptide 1 analog liraglutide (NN2211): 
A 12−week, double−blind, 
randomized, controlled trial. 
Diabetes Care 2004; 
27: 1335−42 
RCT.  12 weeks.  
Randomised to 5 different 
doses of Liraglutide 0.045 
mg, 0.225 mg, 0.45 mg; 
0.60 mg; 0.75 mg  versus 
Placebo or  verusus 
Sulfonylurea - Glimperide  
Excluded - liraglutide 
monotherapy 
Chang A et al.
73
 2003 The GLP−1 derivative NN2211 
restores beta−cell sensitivity to 
glucose in type 2 diabetic patients after 
a single dose. 
Diabetes 2003; 52: 
1786−91 
RCT- two-period cross-
over trial. 10 patients. 
Assessed the effect of a 
single subcutaneous 
injection of NN2211. There 
was a 3–6 week interval 
between dosing periods. 
Excluded - liraglutide 
monotherapy and 3-6 
weeks duration 
Degn K et al.
74
  2004 One week’s treatment with the long-
acting glucagon like peptide 1 
derivative liraglutide (NN2211) 
markedly improves 24-h glycemia and 
alpha- and beta-cell function and 
reduces endogenous glucose release in 
patients with type 2 diabetes 
Diabetes 2004; 53: 
1187–94 
RCT. Explored the effect 
of short-term (1 week) 
treatment with liraglutide. 
Excluded - liraglutide 
monotherapy and one week 
duration 
Juhl C et al.
75
  2002 Bedtime administration of NN2211, a 
long-acting GLP-1 derivative, 
substantially reduces fasting and 
postprandial glycemia in type 2 
Diabetes 2002; 51: 
424–9 
RCT. 11 patients. A single 
injection (10  g/kg) of 
NN2211 was administered. 
Excluded - liraglutide 
monotherapy and 1-2 days 
duration 
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diabetes.  
Damholt B et 
al.
76
 
2006 An open-label, parallel group study 
investigating the effects of age and 
gender on the pharmacokinetics of the 
once-daily glucagon-like peptide-1 
analogue liraglutide. 
J Clin Pharmacol 
2006; 46: 635–41. 
RCT. 18 healthy subjects. 
Total duration of the trial 
for each subject was 
approximately 5 weeks. 
Excluded - healthy 
subjects, liraglutide 
monotherapy and 5 weeks 
duration 
Nauck M. & 
Marre M.
77
 
2009 Adding liraglutide to oral antidiabetic 
drug monotherapy: efficacy and 
weight benefits. 
Postgrad Med 2009; 
121: 5–15  
Included a subset of 
patients receiving prior 
OAD monotherapy from 2 
phase 3, 26-week TCTs.  
Excluded - combined data 
from sub-set of two RCTs 
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Appendix 2 Nausea – exenatide vs liraglutide 
 
The submission provides a comparison of nausea frequency for both exenatide and liraglutide from 
the LEAD-6 trial. Note that this trial used a 1.8 mg dose of liraglutide. 
The industry submission reports that 
“ in all LEAD studies, the majority of episodes of nausea were mild to moderate, transient and rarely 
led to discontinuation of therapy” 
 
Figure 8 below from the industry submission shows the percentage of subjects with nausea on 
liraglutide and exenatide. The percentage of subjects with at least one gastro-intestinal adverse effect 
increased after the doses were increased (standard practice is to start with a low dose and increase 
after weeks 1-2 and 4 for liraglutide and exenatide respectively) but decreased over time. The overall 
frequency was similar but LEAD-6 reported longer duration of nausea with exenatide as seen in 
Figure 8 (taken from the NN industry submission). 
 
 
Figure 8  LEAD-6: Proportion of subjects with nausea by week and treatment  
 
Novo Nordisk did not include a disutility for nausea in the cost effectiveness analysis on the grounds 
that it was “mild and transient”.  Inclusion would have increased the cost per QALY in comparison 
with glargine and sitagliptin. However the effect would probably be very small. The disutility from 
nausea appears to be low.  It was reported to be a reduction of 0.04 in a study by Matza and 
colleagues  in a study sponsored by Lilly, though it is not clear how many patients in that study were 
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on exenatide (23% were on “injectables”).78  Given the low disutility and the short duration, it would 
be unlikely to significantly affect the cost per QALY.  In routine care, anyone having troublesome 
nausea could change to another drug. Table 43 below, taken from the Industry Submission, gives data 
on the nausea reported in the liraglutide RCTs. 
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Table 43  Nausea reported in the randomised controlled trials 
Study Arm n Nausea 
(% of 
subjects) 
Statistical comparison % 
discontinuing 
due to nausea  
SAE(%)               
1860 Liraglutide 1.2 
mg 
*** ****  * *** 
Liraglutide 1.8 
mg 
*** ****  * * 
Sitaglitpin 100 
mg 
*** ***  * * 
Buse J et 
al. 
2009
19
 
Liraglutide 1.8 
mg 
235 25.5 The incidence of nausea was 
similar initially, it was less 
persistent with liraglutide 
(estimated treatment rate 
ratio 0·448 for liraglutide vs. 
exenatide; proportion of 
participants with nausea at 
week 26, 5 of 202 [3%] vs. 
16 of 186 [9%], p<0.0001 
6 5.1 
Exenatide 10 µg 232 28.0 6.9 2.6 
Russell-
Jones D 
et al. 
2009
18
 
Liraglutide 1.8 
mg 
230 13.9 Significantly greater 
percentage of patients 
experiencing nausea with 
liraglutide compared with 
placebo or insulin glargine, 
p<0.0001 
2 patients 4 
Placebo 114 3.5 0 7 
Insulin glargine 232 1.3 0 8 
Zinman 
B et al. 
2009
17
 
Liraglutide 1.2 
mg 
178 45* No statistical comparisons 
reported 
3 8 patients 
(8 
events) 
Liraglutide 1.8 
mg 
178 56* 11 7 patients 
(10 
events) 
Placebo 177 19* 0 12 
patients 
(13 
events) 
Marre M 
et al. 
2009
62
 
Liraglutide 0.6 
mg 
233 5.2 No statistical comparisons 
reported 
0.9-2.2 3 
Liraglutide 1.2 
mg 
228 10.5 0.9-2.2 4 
Liraglutide 1.8 
mg 
234 6.8 0.9-2.2 5 
Placebo  114 1.8 0.9-2.2 3 
Rosiglitazone 231 2.6 0.9-2.2 3 
Nauck 
M et al. 
2009
61
 
Liraglutide 0.6 
mg 
242  10.7 No statistical comparisons 
reported 
1* 3.3 
Liraglutide 1.2 
mg 
240 16.3 5* 5.8 
Liraglutide 1.8 
mg 
242 18.6 8* 3.7 
 Glimepiride 242 3.3  0* 4.1 
Placebo 121 4.1 0* 3.3 
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We compared the frequency of nausea on exenatide in LEAD-6, funded by Novo Nordisk, with trials 
of exenatide, nearly funded by its manufacturer Lilly.  In these studies, exenatide was started with 5 
µg for first 4 weeks and then increased to 10 µg twice daily. 
The incidence of nausea on exenatide varied amongst studies, was tended to be higher in the Lilly 
studies than in LEAD-6; 
 Bergenstal 200979:  nausea in 29% on exenatide (versus 9% on insulin). Discontinuation due 
to nausea in 6% on exenatide. 
 Bunck 200920:  mild to moderate nausea in 50% of patients on exenatide  and 9% for glargine. 
 Davies 2009 ( HEELA study)26:  incidence of  nausea was 48%  for  exenatide patients (none 
on glargine) and 2% discontinuation 
 Davis 200726:  incidence of mild to moderate nausea in exenatide = 48.5% ( glargine 12.5%). 
Discontinuation due to nausea on  exenatide = 9% and none in glargine group. 
 DeFronzo 200580: incidence of nausea 45% on exenatide 10-ug  (23% on  placebo). 2% 
discontinuation on exenatide. 
 Gao 200981: incidence of nausea was 25% on exenatide  (placebo 1%), with 4% 
discontinuation due to nausea. 
 Heine 200522: incidence of nausea  on exenatide was 57%  (glargine 9%). 
 Drucker 200882: incidence of exenatide 35%  given twice daily;  it was lower  (26.4%)   with 
once weekly administration) 
 Kadowaki 200983:  in exenatide group  the incidence of nausea was 35% and withdrawals due 
to nausea were 4%. 
 Nauck 200784:  in the exenatide group the  incidence of nausea in group was  33%  (compared 
to 0.4% in the insulin  group), with 3.5% discontinuation due to nausea 
 Zinman 200785:  incidence of  40% nausea in  exenatide group (compared to 15% on placebo) 
with 9% withdrawal due to nausea. 
 
Nausea was reported at a higher incidence during the initial weeks of therapy (weeks 0–8) and 
declined thereafter (see below). This fits with the longer duration of nausea with exenatide in LEAD- 
6.  Gao and colleagues reported that the highest incidence of nausea in the exenatide group was 
reported between week 4 and week 8, after which it decreased (week 12–16, 2%).81  Kadowaki and 
colleagues
83
 reported higher frequency in the first 8 weeks with less thereafter, as did Kendall and 
colleagues.
86
 
 
So the frequency of nausea on exenatide  in LEAD-6 was lower than in most other trials. 
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Note that the reduced frequency is because nausea with liraglutide wears off much more quickly than 
with exenatide. Initial rates are similar. 
 
 
Explanations for the lower prevalence of nausea with liraglutide compared to exenatide could include 
the once daily rather than twice daily dosage, which may provide less of a peak and trough situation. 
Support for this comes from the trial of long-acting exenatide versus twice daily exenatide where 
nausea and vomiting were much less frequent with the weekly form.
82
  Liraglutide injection produces 
maximal concentrations within 10-14 hour after administration with a half life of 13 hour compared to 
exenatide that reaches maximum concentrations within 2 to 3 hours and a half life of 2.4 hours. 
 
 Rosenstock  and colleagues compared  albiglutide and exenatide and noted less nausea with the  
former given weekly.
37
 They conclude that the reasons for differences in the tolerability of albiglutide 
and exenatide are not known but suggest that the difference could be due to the differences in 
pharmacokinetics including gradual absorption (Tmax is ~ 3 days for albiglutide and ~2.1 hr for 
exenatide) and a long plasma half life of ~5 days resulting in a steady state achieved after 4-5 doses 
for 30 mg weekly. In addition the slow accumulation of albiglutide may help tolerate GI adverse 
events and also the relative impermeability of albiglutide to the central nervous system may have 
resulted in a lower incidence of nausea and vomiting than exenatide.  
 
Nauck and colleagues compared different doses of taspoglutide against placebo, and reported that the 
frequency of nausea was less (10%) with 20mg every two weeks than 10mg weekly (24%).
36
 
 
Barnett suggests in his review that the lower frequency of nausea with weekly exenatide may be due 
to the more gradual increase in plasma exenatide concentrations with exenatide LAR.  He adds that 
the gradual introduction of exenatide has shown to reduce the incidence of nausea by about 50%. 
87
 
 
Another possible reason could be the greater homology of liraglutide with human GLP-1 than 
exenatide (97% versus 53%), as shown in Figure 9 below (taken from Chia and Egan 
88
 – permission 
not yet obtained so in confidence).  By homology, we mean that liraglutide is more similar to human 
GLP-1.  However, there does not seem to be any evidence on whether the incidence of nausea is 
related to the homology of the drugs.  
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Figure 9  Structure of native GLP-1, exenatide and liraglutide (from Chia and Egan 2008) 
 
 
The difference in nausea is very unlikely to be due to chance, given the p value of 0.0001 (industry 
submission Table 11 page 37). 
 
We conclude that there does seem to be less nausea with liraglutide compared to exenatide , and that 
this may be related to the frequency of dosage. 
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Appendix 3 Comparison of liraglutide 1.2 mg and 1.8 mg doses 
LEAD-1 
 
Difference between Lira 
1.8 mg and Lira 1.2mg 
(1.8mg-1.2mg) 
Liraglutide 1.2 mg 
(+GLIME) 
Liraglutide 1.8 mg 
(+GLIME) 
HbA1c (change from baseline to 
endpoint) %; mean (SD) 
-0.05 (diff in change from 
baseline and vs rosig) 
0.1% (diff in change vs 
placebo) 
-1.08 (1.057) -1.13 (1.071) 
% of patients who achieved a 
target HbA1c level <7% 
7 35 42 
% of patients who achieved a 
target HbA1c level ≤6.5% 
-1 22 21 
Mean change in body weight 
(kg) 
-0.5 0.3 -0.2 
Change in BMI (kg/m2); mean 
(SD) 
-0.202 0.119 (0.901) -0.083 (0) 
Mean reduction in FPG levels -0.02 -1.57 -1.59 
% of patients achieving fasting 
glucose between 5 mmol/L and 
≤7.2 mmol/L 
1 37.00 38 
Reduction in SBP; mean (SD) -0.25 -2.56 (12.835) -2.81 (13.155) 
Major hypo event rate/100 pt. yrs 0.9 0 0.9 
Rate of minor hypos 
(events/patient year) 
-0.04 0.51 0.47 
Minor hypo event rate/100 pt. yrs -3.3 50.5 47.2 
% reporting a minor 
hypoglycaemic episode 
-1.1 9.2 8.1 
Major hypoglycaemic episode 
(no. patients) 
  NR 1 (9 days after 
treatment started) 
Serious adverse events (%) 1 4 5 
Incidence of serious AE 0.01 0.04 0.05 
Nausea (% subject experiencing) -3.7 10.5 6.8 
Started 6 228 234 
Completed 17 196 (86%) 213 (91%) 
Withdrawn -11 32 (14%) 21 (9%) 
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LEAD-2 
 
Difference between Lira 
1.8 mg and Lira 1.2mg 
(1.8mg-1.2mg) 
Liraglutide 1.2 mg 
(+MET) 
Liraglutide 1.8 mg 
(+MET) 
HbA1c (change from baseline to 
endpoint) %; mean (SD) 
0.03 -0.97 (1.087) -1 (1.087) 
% of patients who achieved a 
target HbA1c level <7% 
7.1 35.3 42.4 
% of patients who achieved a 
target HbA1c level ≤6.5% 
4.8 19.8 24.6 
Mean change in body weight 
(kg) mean (SE) 
-0.2 -2.6 (0.2) -2.8 (0.2) 
Change in BMI (kg/m
2
); mean 
(SD) 
0.076 -0.907 (0.936) -0.983 (1.01) 
FPG (at end of the study) 
mmol/L mean (SE) 
0 8.5 (2.6) 8.5 (2.4) 
Decrease in FPG from baseline 
(mmol/L) 
-0.1 -1.6 -1.7 
Reduction in SBP (mm Hg); 
mean (SD) 
0.52 -2.81 (13.351) -2.29 (12.912) 
Overall rate of hypos 
(events/year) 
  0.03 to 0.14 
Minor hypo event rate/100 pts 5.9 2.8 8.7 
Incidence of minor hypos   Approx. 3% 
No major hypoglycaemic events reported 
% reporting nausea,vomiting & 
diarrhoea 
4 40 44 
% reporting nausea only 3 16 19 
Started       
Randomized 1 241 242 
Exposed (ITT and safety 
population) 
2 240 242 
Completed -6 197 191 
Withdrawn (%) 7 44 (18) 51 (21) 
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LEAD-4 
 
Difference between 
Lira 1.8 mg and Lira 
1.2mg (1.8mg-1.2mg) 
Liraglutide 1.2 mg 
(+MET + ROSI) 
Liraglutide 1.8 
mg (+MET + 
ROSI) 
HbA1c % (change in from 
baseline to study end); mean 
(SE)% 
0 -1.5 (0.1) -1.5 (0.1) 
% of patients who achieved a 
target HbA1c level <7% 
-3.8 57.5 53.7 
% of patients who achieved a 
target HbA1c level ≤6.5% 
-1.1 37.3 36.2 
Mean change in body weight from 
baseline (kg); mean (SE) 
-1.0 -1.0 (0.3) -2.0 (0.3) 
FPG end-of-study values 
(mmol/L); mean (SE) 
-0.1 7.7 (2.7) 7.6 (2.3) 
Decrease in FPG from baseline 
(mmol/L) 
-0.2 -2.2 -2.4 
SBP - mean change from baseline 
(mmHg); mean (SE) 
1.1 -6.7 (1.1) -5.6 (1.1) 
Severe hypoglycaemic episode 
(no. patients) 
  None None 
Hypoglycaemia - minor 
(events/subject year) 
0.2 0.4 0.6 
Incidence of minor 
hypoglycaemia % 
-1.1 9 7.9 
Serious adverse events (number)   8 subjects (8 total 
events) 
7 subjects (10 total 
events) 
% reporting nausea (one or more 
episodes) 
11 29 40 
% reporting ≤7 days of nausea 
(first 8 weeks of treatment) 
  71 to 84 
Randomised 0 178 178 
Completed n(%) -20 153 (86) 133 (75) 
Withdrawn n(%) 20 25 (14) 45 (25) 
 
  
Copyright 2010 Queen's Printer and Controller of HMSO. All rights reserved.
98 
 
 
Unpublished (Trial 
ID: NN2211-1860):  
 
Difference between Lira 1.8 mg and 
Lira 1.2mg (1.8mg-1.2mg) 
Liraglutide 1.2 mg 
(+MET) 
Liraglutide 1.8 mg 
(+MET) 
HbA1c (change from 
baseline to endpoint) 
% 
***** *************** *************** 
% of patients who 
achieved a target 
HbA1c level <7% 
******************************* ** * 
% of patients who 
achieved a target 
HbA1c level ≤6.5% 
******************************* **** * 
Mean change in 
body weight from 
baseline(kg) 
***** **************** * 
BMI change (kg/m
2
) ***** ************ **************** 
FPG - mean change 
from baseline 
(mmol/L) 
***** **************** * 
SBP - mean change 
from baseline 
(mmHg) 
***** **************** **************** 
Hypoglycaemia - 
major (events per 
100 patient years) 
** * * 
Hypoglycaemia - 
minor (events/100 
patient years) 
**** **** **** 
Hypoglycaemia - 
minor 
(events/subject year) 
**** **** **** 
Hypoglycaemia - 
minor (% of 
subjects) 
***** *** *** 
Serious adverse 
events (%) 
**** **** **** 
Nausea (% subject 
experiencing) 
**** ***** ***** 
Randomised * *** *** 
Completed ** *** *** 
Withdrawn ** ** ** 
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Appendix 4 The CORE model 
The CORE model is a highly developed and well-tested model, and one of the foremost of its kind.  
Palmer and colleagues outlined the broad structure of the CORE model for both T1DM and T2DM 
patients.
55
 
 
The CORE model can be briefly summarised as being an internet based model which is based upon 15 
sub-models which simulate the main complications of diabetes. Each sub-model is a Markov model 
which employs Monte Carlo simulation which incorporates the time, the state, the time in state and 
transition probabilities which are typically diabetes type dependent as derived from published sources.  
A common problem with standard Markov modelling is the requirement that distinct mutually 
exclusive memory-less disease states have to be specified. This approach would overlook the 
interactions between the different complications of diabetes unless a prohibitively large number of 
disease states were defined.  CORE modelling uses tracker variables to allow interactions between the 
different sub-models, with the progression of one or more complications influencing the transition 
probabilities in other sub-models where a relationship has been established.  For instance, the risk of a 
first myocardial infarction is linked to whether gross proteinuria, microalbumina or end stage renal 
disease has developed, a relative risk being specified for each of these. 
 
The 15 sub-models of CORE are: Myocardial infarction; Angina; Congestive heart failure; Stroke; 
Peripheral vascular disease; Neuropathy; Foot ulcer, with possible amputation; Retinopathy; Macular 
Oedema; Cataract; Nephropathy; Hypoglycaemia; Ketoacidosis; Lactic Acidosis; and, General 
mortality. Note that a specific mortality is associated with the Myocardial infarction; Congestive heart 
failure; Stroke; Foot ulcer, with possible amputation; Nephropathy; Hypoglycaemia; Ketoacidosis and 
Lactic Acidosis sub-models.  For hypoglycaemia the specific mortality is specified by the user. 
Not all sub-models are differentiated by diabetic type.  Myocardial infarction, angina, stroke, 
peripheral vascular disease and foot ulcers leading to amputation are modelled as having the same 
inputs for T1DM patients as for T2DM patients.   
 
The baseline population characteristics within CORE can be specified in terms of age, sex, duration of 
diabetes, racial characteristics, glycemic control, blood pressure, the body mass index, lipid levels, 
smoking and baseline rates of complications. Treatments can be specified as modifying glycemic 
control, hypoglycaemic event rates, severe hypoglycaemic event rates, blood pressure, the body mass 
index and lipid levels. Typically only glycaemic control and hypoglycaemic event rates are specified.  
Palmer and colleagues undertook a validation exercise of the CORE model using published data for 
the incidence of the complications associated with both T1DM and T2DM.
89
  This exercise appears to 
show reasonably good validation for the incidence of the complications examined.   
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Within CORE modelling any improvement in baseline HbA1c as a result of a novel treatment is 
typically assumed to be sustained. There is the possibility that while an improvement may be 
observed over a period of time, this relative improvement in HbA1c may be eroded in the medium to 
long term. While CORE does permit some adjustment of this assumption through the use of a long 
term adjustment factor, it does not appear to permit the evolution of the gain in HbA1c to be specified 
in detail. Given this, the longer term adjustment to the relative improvement in HbA1c appears to be 
little used and the absolute gain over baseline HbA1c is typically assumed to be maintained. 
 
Validation 
Diabetes models are (if their developers submit them) tested in the Mount Hood Challenge. In the 
most recent of these, one test for the models was their ability to predict the outcomes of the DCCT 
trial. 
90
 The CORE model was entered in Mount Hood challenge at its 4
th
 and currently latest meeting, 
the results of which have been published. For type 2 diabetics this attempted to model outcomes of the 
CARDS trial of lipid lowering interventions. As such, it may not particularly address model validation 
for  
 the evidence on changes in HbA1c as presented within the mixed treatment comparison of 
the submission, and  
 weight changes  
 
Table 44  Mount Hood challenge results 
4
th
 Mt Hood challenge Acute coronary event Stroke 
 Control Intervention Control Intervention 
CARDS study 5.1 3.2 3.2 1.4 
Validations     
  CDC/RTI 6.4 4.3 1.7 1.5 
  EAGLE 3.9 .. 0.8 .. 
  CARDIFF 6.7 4.5 2.5 2.2 
  UKPDS Outcomes Model 5.3 3.6 2.3 2.0 
  CORE 6.4 4.5 2.0 1.7 
 
Most models including CORE appeared to over predict acute coronary events, though the net impact 
of the intervention was perhaps more accurately predicted. Within the above note that the CARDS 
coronary events included hospitalised unstable angina, silent MIs and resuscitated cardiac arrests. The 
models were typically reporting fatal and non-fatal MIs, which would have been further over 
predicted than the above suggests. 
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But the paper noted that the CARDS patient group was a specially selected low mortality risk group 
with no history of previous CVD or pre-existing major illness, which could have accounted for the 
models over prediction of CV events. 
 
In a comparison with DCCT results, the CORE model gave estimates very close to what was observed 
for renal disease, retinopathy and peripheral neuropathy in the intensive group, and was also close for 
neuropathy and renal disease in the conventional group. It did somewhat under-estimate retinopathy 
in the conventional group. But overall, getting good results in a voluntary challenge reinforces our 
confidence that CORE is a good model. 
 
The submission also notes that the CORE model has undergone a range of 2nd order and 3rd order 
validations, the R
2
 for these being reported as: validation analyses in type 2 diabetes were associated 
with R
2
 values of  
 0.8861 across all validations in type 2 diabetes 
 0.9574 across 2nd order validations 
 0.9023 across 3rd order validations 
 
No further details were provided of this, and the published paper does not appear to particularly 
distinguish between the 2
nd
 order and the 3
rd
 order validations within its presentation, which studies 
were used and what variables the validation exercises simulated. The only additional information 
within the paper related to the R
2
 specific to type 2 diabetes of 0.975 for 2
nd
 order validations and of 
0.8748 for 3
rd
 order validations. 
 
The external consultant nominated by the manufacturer as an expert on CORE is in the course of 
supplying more information about CORE validation. 
 
Cross check of base case results 
The CORE model has recently been updated to allow for depression associated with treatment to be 
included in the analysis. The manufacturer submission was based on the previous version of CORE. 
Re-running the base cases in this version of CORE resulted in results that cross checked with those of 
the submission. For completeness, augmenting the results of the submission with the undiscounted life 
expectancies and the tabulated CEACs, resulted in the following. 
 
Table 45  Updated CORE – trial 1860  
1860 Liraglutide 1.2 Setting 1: Setting 2: Difference mean Difference SD 
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Treatment tree Liraglutide 1.2 Sitagliptin S1 - S2 S1 - S2 
Life Expectance 11.75 11.64 0.119 0.226 
Undiscounted Life Expectancy 16.75 16.52 0.226 .. 
Quality-Adjusted Life Expectancy 7.52 7.33 0.187 0.145 
Direct Costs £21,793 £19,951 £1,842 £715 
Treatment £9,185 £7,129 £2,056 .. 
 
Willingness to pay Prob S1 c/e 
ICER £9,851/QALY 
£0 0.3 
£10,000 52.0 
£20,000 77.5 
£30,000 82.1 
£40,000 84.7 
£50,000 85.9 
£60,000 86.4 
£70,000 86.8 
£80,000 87.0 
£90,000 87.1 
£100,000 87.4 
 
1860 Liraglutide 1.8 Setting 1: Setting 2: Difference mean Difference SD 
Treatment tree Liraglutide 1.8 Sitagliptin S1 - S2 S1 - S2 
Life Expectance 11.87 11.64 0.23 0.226 
Undiscounted Life Expectancy 16.97 16.52 0.45 .. 
Quality-Adjusted Life Expectancy 7.64 7.33 0.308 0.151 
Direct Costs £23,175 £19,951 £3,224 £683 
Treatment £10,968 £7,129 £3,839 .. 
 
Willingness to pay Prob S1 c/e 
ICER £10,465/QALY 
£0 0 
£10,000 44.4 
£20,000 85.7 
£30,000 92.3 
£40,000 94.2 
£50,000 95.4 
£60,000 95.9 
£70,000 96.2 
£80,000 96.3 
£90,000 96.4 
£100,000 96.6 
 
These values correspond with those of Tables 31 and 32 of the submission. The probability of cost 
effectiveness values for willingness to pay values of £20,000 per QALY and £30,000 per QALY 
correspond with figure 14 and the text of the submission. 
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Table 46  Updated  CORE – LEAD -6 
 
LEAD6 Liraglutide 1.8 Setting 1: Setting 2: Difference mean Difference SD 
Treatment tree Liraglutide 1.8 Exenatide S1 - S2 S1 - S2 
Life Expectance 11.58 11.43 0.152 0.211 
Undiscounted Life Expectancy 16.45 16.15 0.3 .. 
Quality-Adjusted Life Expectancy 7.44 7.28 0.163 0.136 
Direct Costs £23,139 £21,501 £1,638 £804 
Treatment £10,963 £8,878 £2,085 .. 
 
Willingness to pay Prob S1 c/e 
ICER £10,054/QALY 
£0 2.4 
£10,000 51.0 
£20,000 74.7 
£30,000 80.6 
£40,000 83.0 
£50,000 84.5 
£60,000 85.3 
£70,000 85.7 
£80,000 86.3 
£90,000 86.6 
£100,000 86.8 
These values correspond with those of tables 37 and 37 of the submission. The probability of cost 
effectiveness values for willingness to pay values of £20,000 per QALY and £30,000 per QALY 
correspond with figure 19 and the text of the submission. 
 
Table 47 Updated CORE – LEAD-5 
 
LEAD5 Liraglutide 1.8 Setting 1: Setting 2: Difference mean Difference SD 
Treatment tree Liraglutide 1.8 Glargine S1 - S2 S1 - S2 
Life Expectance 11.35 11.18 0.169 0.209 
Undiscounted Life Expectancy 16.07 15.74 0.33 .. 
Quality-Adjusted Life Expectancy 7.30 7.06 0.24 0.14 
Direct Costs £25,109 £21,471 £3,638 £656 
Treatment £11,090 £7,370 £3,720 .. 
 
Willingness to pay Prob S1 c/e 
ICER £15,130/QALY 
£0 0.0 
£10,000 17.0 
£20,000 67.1 
£30,000 81.9 
£40,000 87.4 
£50,000 90.5 
£60,000 92.1 
£70,000 92.7 
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£80,000 93.3 
£90,000 93.5 
£100,000 94.1 
 
These values correspond with those of tables 41 and 42 of the submission. The probability of cost 
effectiveness values for willingness to pay values of £20,000 per QALY and £30,000 per QALY 
correspond with figure 23 and the text of the submission. 
 
Table 48  Updated CORE – LEAD -1 
LEAD1 Liraglutide 1.2 Setting 1: Setting 2: Difference mean Difference SD 
Treatment tree Liraglutide 1.2 TZD S1 - S2 S1 - S2 
Life Expectance 12.20 11.91 0.291 0.218 
Undiscounted Life Expectancy 17.64 17.05 0.587 .. 
Quality-Adjusted Life Expectancy 7.89 7.56 0.332 0.144 
Direct Costs £23,623 £21,559 £2,064 £698 
Treatment £9,840 £7,005 £2,835 .. 
 
Willingness to pay Prob S1 c/e 
ICER £6,226/QALY 
£0 0.1 
£10,000 83.1 
£20,000 96.6 
£30,000 97.7 
£40,000 97.8 
£50,000 98.2 
£60,000 98.3 
£70,000 98.6 
£80,000 98.6 
£90,000 98.7 
£100,000 98.7 
 
LEAD1 Liraglutide 1.8 Setting 1: Setting 2: Difference mean Difference SD 
Treatment tree Liraglutide 1.8 TZD S1 – S2 S1 - S2 
Life Expectance 12.25 11.91 0.341 0.218 
Undiscounted Life Expectancy 17.73 17.05 0.682 .. 
Quality-Adjusted Life Expectancy 7.96 7.56 0.398 0.144 
Direct Costs £25,289 £21,559 £3,730 £718 
Treatment £11,597 £7,005 £4,592 .. 
 
Willingness to pay Prob S1 c/e 
ICER £9,376/QALY 
£0 0 
£10,000 55.8 
£20,000 95.2 
£30,000 98.1 
£40,000 99.1 
£50,000 99.5 
£60,000 99.6 
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£70,000 99.6 
£80,000 99.7 
£90,000 99.7 
£100,000 99.7 
These values correspond with those of table 46 of the submission.  
 
Table 49  Updated CORE – LEAD-2 
 
LEAD2 Liraglutide 1.2 Setting 1: Setting 2: Difference mean Difference SD 
Treatment tree Liraglutide 1.2 Met + SU S1 - S2 S1 - S2 
Life Expectance 11.51 11.41 0.095 0.206 
Undiscounted Life Expectancy 16.30 16.11 0.182 .. 
Quality-Adjusted Life Expectancy 7.44 7.20 0.238 0.136 
Direct Costs £22,903 £19,746 £3,157 £592 
Treatment £9,108 £5,864 £3,244 .. 
 
Willingness to pay Prob S1 c/e 
ICER £13,257/QALY 
£0 0 
£10,000 25.1 
£20,000 74.1 
£30,000 85.3 
£40,000 88.1 
£50,000 90.2 
£60,000 91.7 
£70,000 92.4 
£80,000 92.8 
£90,000 93.2 
£100,000 93.9 
 
LEAD2 Liraglutide 1.8 Setting 1: Setting 2: Difference mean Difference SD 
Treatment tree Liraglutide 1.8 Met + SU S1 - S2 S1 - S2 
Life Expectance 11.50 11.41 0.092 0.203 
Undiscounted Life Expectancy 16.29 16.11 0.177 .. 
Quality-Adjusted Life Expectancy 7.44 7.20 0.245 0.134 
Direct Costs £24,606 £19,746 £4,860 £594 
Treatment £10,817 £5,864 £4,953 .. 
 
Willingness to pay Prob S1 c/e 
ICER £19,837/QALY 
£0 0 
£10,000 1.9 
£20,000 51.6 
£30,000 74.3 
£40,000 82.2 
£50,000 86.7 
£60,000 89.2 
£70,000 91.1 
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£80,000 92.1 
£90,000 92.6 
£100,000 93.1 
These values correspond with those of table 47 of the submission.  
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Appendix 5 Indexation and cross check of appendix 13 of the submission 
 
The PSSRU: Unit Costs of Health and Social Care notes that “Hospital and community health 
services (HCHS) pay and price inflation is a weighted average of two separate inflation indices: the 
pay cost index (PCI) and the health service cost index (HSCI). The PCI measures pay inflation in the 
HCHS. The PCI is itself a weighted average of increases in unit staff costs for each of the staff groups 
within the HCHS sector. Pay cost inflation tends to be higher than pay settlement inflation because of 
an element of pay drift within each staff group. Pay drift is the tendency for there to be a gradual shift 
up the incremental scales, and is additional to settlement inflation. The estimate of pay inflator for the 
current year is based on information supplied by the Department of Health and is based on pay 
awards of NHS staff. The HSCI is calculated monthly to measure the price change for each of 40 sub-
indices of goods and services purchased by the HCHS. The sub-indices are weighted together 
according to the proportion of total expenditure which they represent to give the overall HSCI value. 
The pay cost index and the health service cost index are weighted together according to the 
proportion of HCHS expenditure on each. This provides an HCHS combined pay and prices inflation 
figure.”  
 
The NICE 2008 Guide to The Methods of Technology Appraisal does not specify the price index that 
should be applied, but from the above it seems reasonable to apply the HCHS index to costs.
91
 Table 
A-44 of the submission outlines that the modelling has applied the HSCI. The differences between the 
three indices within the PSSRU: Unit Costs of Health and Social Care are outlined below: 
 
Table 50 Differences amongst indexation indices 
 
 Prices (HSCI) Pay (PCI) Pay and Prices (HSCS) 
 Index Inflation 2008 CF Index Inflation 2008 CF Index Inflation 2008 CF 
1994/95 100.0 0.00% 1.20 100.0 0.00% 1.93 100.0 0.00% 1.61 
1995/96 103.2 3.20% 1.17 104.4 4.40% 1.85 104.0 4.01% 1.55 
1996/97 104.7 1.50% 1.15 107.8 3.30% 1.79 106.9 2.77% 1.51 
1997/98 105.2 0.40% 1.15 110.5 2.50% 1.74 108.7 1.70% 1.48 
1998/99 107.8 2.50% 1.12 116.0 4.90% 1.66 113.0 3.98% 1.42 
1999/00 109.1 1.20% 1.10 124.0 6.90% 1.56 118.2 4.55% 1.36 
2000/01 108.8 -0.30% 1.11 132.9 7.20% 1.45 123.1 4.19% 1.31 
2001/02 108.9 0.10% 1.11 143.9 8.30% 1.34 129.4 5.09% 1.24 
2002/03 110.0 1.00% 1.10 151.1 5.00% 1.28 133.9 3.49% 1.20 
2003/04 111.6 1.50% 1.08 162.1 7.30% 1.19 140.9 5.19% 1.14 
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2004/05 112.7 1.00% 1.07 169.4 4.50% 1.14 145.4 3.20% 1.11 
2005/06 114.9 1.90% 1.05 178.9 5.60% 1.08 151.2 4.01% 1.06 
2006/07 118.3 3.00% 1.02 185.0 3.40% 1.04 155.8 3.03% 1.03 
2007/08 120.4 1.80% 1.00 192.8 4.20% 1.00 161.0 3.34% 1.00 
 2008 CF: multiplicative conversion factor to convert a cost in the base year into 2008 prices 
 
In the light of the above, as an example for costs in 1999 prices inflating these to 2008 prices using 
the HSCS would result in a 42% uplift as compared to a 12% uplift using the HSCI: the HSCS would 
result in a 27% higher cost than the HSCI. 
 
A cross check of the conformity of Table A-44 with Base case NICE costs in the CORE model 
implementation within the NICE1 userspace, coupled with the implications of the above result in: 
 
Table 51 Cross-check base case costs and indexations 
 Base Submission HCSI HCSC 
Description of event or state Year Cost 2008 Inf X-Check Diff X-Check Diff 
Fatal MI 1999 £1,152 £1,291 £1,287 -0.3% £1,641 27.1% 
MI, year 1 1999 £4,385 £4,914 £4,899 -0.3% £6,244 27.1% 
MI, year 1+ 1999 £722 £809 £807 -0.3% £1,028 27.1% 
Angina, year 1 1999 £2,274 £2,548 £2,541 -0.3% £3,238 27.1% 
Angina, year 1+ 1999 £751 £842 £839 -0.3% £1,069 27.0% 
Congestive heart failure, year 1 1999 £2,536 £2,842 £2,834 -0.3% £3,611 27.1% 
Congestive heart failure, year 1+ 1999 £889 £996 £993 -0.3% £1,266 27.1% 
Stroke, fatal 1999 £3,383 £3,791 £3,780 -0.3% £4,818 27.1% 
Stroke, year 1 1999 £2,682 £3,006 £2,997 -0.3% £3,819 27.1% 
Stroke, year 1+ 1999 £507 £568 £566 -0.3% £722 27.1% 
Peripheral vascular disease, year 1 1997 £2,270 £2,618 £2,610 -0.3% £3,418 30.6% 
Not listed in sub: PVD year 1+   £2,618     
Haemodialysis 1997 £24,160 £27,863 £27,780 -0.3% £36,382 30.6% 
Peritoneal dialysis 1997 £18,140 £20,920 £20,858 -0.3% £27,316 30.6% 
Kidney transplant, year 1 2002 £20,000 £22,191 £22,126 -0.3% £24,881 12.1% 
Kidney transplant, year 1+ 2002 £6,500 £7,212 £7,191 -0.3% £8,086 12.1% 
Retinal photocoagulation 1997 £655 £755 £753 -0.2% £986 30.6% 
Severe vision loss/blindness, year 1 1999 £872 £977 £974 -0.3% £1,242 27.1% 
Severe vision loss/blindness, year 1+ 1999 £281 £315 £314 -0.3% £400 27.0% 
Cataract extraction 1999 £1,553 £1,740 £1,735 -0.3% £2,212 27.1% 
Cataract annual follow-up 1999 £105 £118 £117 -0.6% £150 26.7% 
Neuropathy, year 1 1997 £924 £1,066 £1,062 -0.3% £1,391 30.5% 
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Neuropathy, year 1+   £1,066     
Uninfected ulcer 1999 £1,251 £1,402 £1,398 -0.3% £1,781 27.1% 
Infected ulcer 1999 £1,282 £1,437 £1,432 -0.3% £1,826 27.0% 
Gangrene 1999 £2,060 £2,308 £2,302 -0.3% £2,934 27.1% 
Amputation, year 1 1999 £8,774 £9,832 £9,803 -0.3% £12,495 27.1% 
Amputation, year 1+ 1999 £558 £625 £623 -0.2% £795 27.1% 
Major hypoglycaemic event 2002 £377 £412 £417 1.2% £469 13.8% 
Not listed in sub: Ketoacidosis event   £897     
Not listed in sub: Lactic acid event   £0     
Annual cost aspirin 
CORE 
2003 £20 £22 
£5 
£22 -0.4% £24 9.3% 
Annual cost statins 
CORE 
2003 £355 £389 
£12 
£389 0.0% £427 9.7% 
Annual costs ACE-I 
CORE 
2003 £235 £257 
£32 
£257 0.2% £283 9.9% 
Costs of screening for retinopathy 
CORE Screen retinopathy+MA 
1999 £33 £37 
£36 
£37 -0.3% £47 27.0% 
Costs of screening for nephropathy 
CORE Screen foot+GRP 
2003 £32 £35 
£23 
£35 0.1% £38 9.9% 
Costs (monthly) non-standard ulcer 
CORE cost 
2003 £220 £241 
£246 
£241 0.0% £264 9.7% 
 2008 Inf: costs inflated in the submission to 2008 prices 
 
Where figures in bold were not found within Base case NICE costs. Figures in italics are those 
applied within the CORE modelling, where these differ from those within the submission. 
 
The 2008 costs of the submission cross check with the application of the HSCI, but are a significant 
underestimate of the costs that would apply through application of the HSCS. The manufacturer has 
supplied an additional set of base case analyses that apply the HSCS index. 
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Appendix 6 Additional sensitivity analyses undertaken by the ERG 
The following additional sensitivity analyses were undertaken by the ERG in order to better 
understand the respective contributions of the individual CORE clinical parameter inputs 
contributions to the changes in life expectancy, QALYs and costs reported within the base cases of the 
submission. These sensitivity analyses were undertaken for the three main trials: 1860, LEAD5 and 
LEAD-6. 
 
Table 52 Additional ERG sensitivity analyses 
Changes from baseline:  
Sensitivity analysis 1  
Price Base case changes 
Weight No change 
Cholesterol No changes 
SBP No change 
HbA1c No change 
Sensitivity analysis 2a  
Price Base case changes 
Weight Base case changes 
Direct BMI disutility 0 
Cholesterol No changes 
SBP No change 
HbA1c No change 
Sensitivity analysis 2b  
Price Base case changes 
Weight Base case changes 
Direct BMI disutility Lee, as per base case 
Cholesterol No changes 
SBP No change 
HbA1c No change 
Sensitivity analysis 3  
Price Base case changes 
Weight No change 
Cholesterol Base case changes 
SBP No change 
HbA1c No change 
Sensitivity analysis 4  
Price Base case changes 
Weight No change 
Cholesterol No changes 
SBP Base case changes 
HbA1c No change 
Sensitivity analysis 5  
Price Base case changes 
Weight No change 
Cholesterol No changes 
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SBP No change 
HbA1c Base case changes 
 
In the tables below the sensitivity analysis applying only the direct drug costs relates to there being no 
clinical effect. The basecase is as per the manufacturer estimates with all clinical effects applied. The 
difference between the basecase and there being no clinical effect is tabulated as an absolute 
difference. Figures given as percentages show the impact of the sensitivity analysis of a selectively 
applied clinical effect as a percentage of the difference between no clinical effect and the base case of 
all clinical effects applying. 
 
Table 53  Results of additional ERG sensitivity analyses – 1860 
1860 Liraglutide 1.2mg  
Liraglutide 1.2mg vs sitagliptin 100mg Life expectancy QALYs (disc) Treatment Costs Total Costs  
********  ***** **** **** ***** ****** **** ******* ***** 
*** ********************** ***** * **** * ****** * ******* * 
**** ******************************** ***** ** **** *** ****** ** ******* *** 
**** ***************************** ***** ** **** **** ****** ** ******* *** 
*** *************************** ***** ** **** *** ****** ** ******* ** 
*** *** ***** ** **** *** ****** ** ******* *** 
*** ***** ***** *** **** **** ****** *** ******* **** 
******  * *** * *** * *** * **** 
          
  Sitagliptin 100mg  
  Life expectancy QALYs (disc) Treatment Costs Total Costs  
********  ***** **** **** ***** ****** **** ******* ***** 
*** ********************** ***** * **** * ****** * ******* * 
**** ******************************** ***** ** **** *** ****** ** ******* *** 
**** ***************************** ***** ** **** **** ****** ** ******* *** 
*** *************************** ***** ** **** *** ****** ** ******* ** 
*** *** ***** ** **** *** ****** ** ******* *** 
*** ***** ***** *** **** **** ****** *** ******* *** 
******  * **** * *** * **** * *** 
          
  Net Effect  
  Life expectancy QALYs (disc) Treatment Costs Total Costs  
********  **** **** **** **** ****** *** ****** ***** 
*** ********************** **** * **** * ****** * ****** * 
**** ******************************** **** ** **** ** ****** ** ****** **** 
**** ***************************** **** ** **** *** ****** ** ****** **** 
*** *************************** ***** *** ***** *** ****** *** ****** *** 
*** *** **** *** **** *** ****** *** ****** *** 
*** ***** **** *** **** *** ****** *** ****** **** 
******  * *** * *** * *** * **** 
 
1860  Liraglutide 1.8mg  
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Liraglutide 1.8mg vs sitagliptin 100mg Life expectancy QALYs (disc) Treatment Costs Total Costs  
******** * ***** **** **** ***** ******* **** ******* ****** 
*** ********************** ***** * **** * ******* * ******* * 
**** ******************************** ***** ** **** *** ******* ** ******* *** 
**** ***************************** ***** ** **** **** ******* ** ******* *** 
*** *************************** ***** *** **** *** ******* *** ******* *** 
*** *** ***** ** **** ** ******* ** ******* *** 
*** ***** ***** *** **** ***** ******* *** ******* *** 
****** * * **** * *** * *** * *** 
          
  Sitagliptin 100mg  
  Life expectancy QALYs (disc) Treatment Costs Total Costs  
******** * ***** **** **** ***** ****** **** ******* ***** 
*** ********************** ***** * **** * ****** * ******* * 
**** ******************************** ***** ** **** *** ****** ** ******* *** 
**** ***************************** ***** ** **** **** ****** ** ******* *** 
*** *************************** ***** ** **** *** ****** ** ******* ** 
*** *** ***** ** **** *** ****** ** ******* *** 
*** ***** ***** *** **** **** ****** *** ******* *** 
****** * * **** * *** * **** * *** 
          
  Net Effect  
  Life expectancy QALYs (disc) Treatment Costs Total Costs  
******** * **** **** **** **** ****** **** ****** ***** 
*** ********************** **** * **** * ****** * ****** * 
**** ******************************** **** ** **** ** ****** ** ****** *** 
**** ***************************** **** ** **** *** ****** ** ****** *** 
*** *************************** **** *** **** ** ****** *** ****** *** 
*** *** **** ** **** *** ****** *** ****** *** 
*** ***** **** *** **** *** ****** *** ****** **** 
****** * * *** * *** * *** * **** 
 
Table 54 Results of additional ERG sensitivity analyses – LEAD 5 
LEAD5 Liraglutide 1.8mg  
Liraglutide 1.8mg vs glargine Life expectancy QALYs (disc) Treatment Costs Total Costs  
Basecase   16.07 0.76 7.30 -0.28 £11,090 £261 £25,109 -£869 
SA1 Only direct drug costs 15.30   7.58   £10,829   £25,978   
SA2a Weight: no direct utility effect 15.34 5% 7.60 -6% £10,844 6% £26,036 -7% 
SA2b Weight: direct utility effect 15.34 5% 6.99 209% £10,844 6% £26,036 -7% 
SA3 Cholesterol & triglycerides 15.23 -10% 7.56 8% £10,807 -8% £25,910 8% 
SA4 SBP 15.43 17% 7.64 -22% £10,874 17% £25,901 9% 
SA5 HbA1c 16.00 91% 7.94 -128% £11,057 87% £24,925 121% 
SA2b-5     104%   67%   102%   131% 
          
  Glargine  
  Life expectancy QALYs (disc) Treatment Costs Total Costs  
Basecase   15.74 0.43 7.06 -0.52 £7,370 £140 £21,471 -£908 
SA1 Only direct drug costs 15.30   7.58   £7,230   £22,379   
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SA2a Weight: no direct utility effect 15.30 0% 7.58 0% £7,233 2% £22,397 -2% 
SA2b Weight: direct utility effect 15.30 0% 6.88 134% £7,231 1% £22,395 -2% 
SA3 Cholesterol & triglycerides 15.19 -27% 7.54 8% £7,193 -26% £22,375 0% 
SA4 SBP 15.29 -3% 7.58 1% £7,226 -3% £22,374 1% 
SA5 HbA1c 15.92 142% 7.90 -61% £7,427 141% £21,478 99% 
SA2b-5     112%   83%   112%   98% 
          
  Net Effect  
  Life expectancy QALYs (disc) Treatment Costs Total Costs  
Basecase   0.17 0.17 0.24 0.24 £3,720 £121 £3,638 £39 
SA1 Only direct drug costs 0.00   0.00   £3,599   £3,599   
SA2a Weight: no direct utility effect 0.02 12% 0.02 7% £3,611 10% £3,639 103% 
SA2b Weight: direct utility effect 0.02 12% 0.11 48% £3,613 12% £3,641 108% 
SA3 Cholesterol & triglycerides 0.02 14% 0.02 8% £3,614 12% £3,535 -164% 
SA4 SBP 0.08 45% 0.07 28% £3,648 40% £3,527 -185% 
SA5 HbA1c 0.04 25% 0.04 18% £3,630 26% £3,447 -390% 
SA2b-5     96%   102%   90%   -631% 
 
Table 55 Results of additional ERG sensitivity analyses – LEAD 6 
LEAD-6 Liraglutide 1.8mg  
Liraglutide 1.8mg vs exenatide 10μg bd Life expectancy QALYs (disc) Treatment Costs Total Costs  
Basecase   16.45 0.80 7.44 -0.52 £10,963 £269 £23,139 -£1044 
SA1 Only direct drug costs 15.65   7.96   £10,694   £24,183   
SA2a Weight: no direct utility effect 15.69 4% 7.97 -2% £10,704 4% £24,192 -1% 
SA2b Weight: direct utility effect 15.69 4% 7.13 160% £10,704 4% £24,192 -1% 
SA3 Cholesterol & triglycerides 15.69 4% 7.97 -3% £10,706 4% £24,162 2% 
SA4 SBP 15.70 6% 7.99 -5% £10,710 6% £24,126 5% 
SA5 HbA1c 16.29 80% 8.30 -66% £10,902 77% £23,173 97% 
SA2b-5     95%   86%   91%   103% 
          
  Exenatide 10μg bd 
  Life expectancy QALYs (disc) Treatment Costs Total Costs  
Basecase   16.15 0.50 7.28 -0.68 £8,878 £171 £21,501 -£695 
SA1 Only direct drug costs 15.65   7.96   £8,707   £22,196   
SA2a Weight: no direct utility effect 15.68 6% 7.97 -1% £8,716 5% £22,210 -2% 
SA2b Weight: direct utility effect 15.68 6% 7.11 125% £8,716 5% £22,210 -2% 
SA3 Cholesterol & triglycerides 15.61 -8% 7.94 3% £8,692 -9% £22,155 6% 
SA4 SBP 15.70 9% 7.98 -4% £8,721 8% £22,181 2% 
SA5 HbA1c 16.13 96% 8.21 -37% £8,861 90% £21,522 97% 
SA2b-5     104%   87%   95%   103% 
          
  Net Effect  
  Life expectancy QALYs (disc) Treatment Costs Total Costs  
Basecase   0.15 0.15 0.16 0.16 £2,085 £98 £1,638 -£349 
SA1 Only direct drug costs 0.00   0.00   £1,987   £1,987   
SA2a Weight: no direct utility effect 0.00 1% 0.00 1% £1,988 1% £1,981 2% 
SA2b Weight: direct utility effect 0.00 1% 0.02 11% £1,988 1% £1,981 2% 
SA3 Cholesterol & triglycerides 0.04 28% 0.03 20% £2,014 28% £2,007 -6% 
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SA4 SBP 0.00 1% 0.00 2% £1,989 2% £1,944 12% 
SA5 HbA1c 0.08 54% 0.09 56% £2,041 55% £1,651 96% 
SA2b-5     84%   90%   86%   105% 
 
These sensitivity analyses had been requested from the manufacturer, but in spite of the clarification 
below there remained some confusion as to what had been requested and it appears that the additional 
sensitivity analyses undertaken by the manufacturer did not correspond to those above. The 
manufacturer has been sent copies of the above sensitivity analyses for comment. 
 
The intention was: 
 Where Base Case Changes use Baseline value plus Basecase Change 
 Where No change or No Changes use Baseline value(s) 
  
For instance, a hypothetical basecase simulation for one treatment arm within the NN submission would have 
applied the Baseline value plus the Basecase changes across all the variables listed. For the sensitivity analysis 
5 the set of Sensitivity Values within the corresponding treatment arm should be applied. 
 
Table 56 Sensitivity analyses requested 
S.A. No. 5   Baseline value Basecase change NN Basecase value Value for S.A. No. 5 
Price Base case changes £0 +£50 £50 £50 
Weight No change Wbase: e.g. 30 +Wch ; e.g. +3 Wbase+Wch [33] Wbase [30] 
Cholesterol No changes X, Y, Z +A, +B, +C X+A, Y+B, Z+C X, Y, Z 
SBP No change SBPbase + SBPch SBPbase+SBPch SBPbase 
HbA1c Base case changes 8.5% -0.5% 8.5%-0.5% 8.0% 
 
If the above related to the 1.2 liraglutide arm, the parallel set of selective changes should be made within the 
comparator arm of the sensitivity analysis simulation, and the simulation set running within the NICE1 
userspace of CORE [old version: http://www.core-diabetes.com/cdmold/].  
  
This should be relatively easily implementable given the clone function of CORE. It is recognized that these are 
not necessarily realistic representations of the clinical situation. But they are desirable to shed light upon the 
contribution of individual parameters to the end aggregate result. It is also recognized that the sum of the 
individual effects within the sensitivity analyses will not equal the aggregate effect of all the changes as 
implemented within the basecase. 
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 Appendix 7 Weight  changes direct utility effects 
The manufacturer has confirmed that for the base case modelling with the application of the Lee -0.01 
disutility per BMI point above 25kg/m2 that a patient modelled as surviving 12 years the following 
direct utility gains from weight changes alone would apply: 
 
Table 57 Direct utility gains from weight changes 
Glimepride From  To Excess Annual Annual Period Period  
1st line year 1-5 BMI ΔBMI BMI BMI25+ Disutil Net Undisc Disc %Total 
Lira 1.2 31.000 -0.907 30.093 5.093 -0.051 0.012 0.062 0.058 24% 
Lira 1.8 31.000 -0.983 30.017 5.017 -0.050 0.013 0.066 0.061 25% 
Glimepride 31.000 0.330 31.330 6.330 -0.063     
2nd line year 6-12     Disutil Net Undisc Disc %Total 
Lira 1.2 30.093 0.577 30.670 5.670 -0.057 0.012 0.087 0.066 28% 
Lira 1.8 30.017 0.577 30.594 5.594 -0.056 0.013 0.092 0.070 29% 
Glimepride 31.330 0.577 31.907 6.907 -0.069     
Total year 1-12      Net Undisc Disc %Total 
Lira 1.2      0.012 0.148 0.124 52% 
Lira 1.8      0.013 0.158 0.131 54% 
Rosiglitazone From  To Excess Annual Annual Period Period  
1st line year 1-5 BMI ΔBMI BMI BMI25+ Disutil Net Undisc Disc %Total 
Lira 1.2 29.900 0.119 30.019 5.019 -0.050 0.007 0.033 0.030 9% 
Lira 1.8 29.900 -0.083 29.817 4.817 -0.048 0.009 0.043 0.040 10% 
Rosiglitazone 29.900 0.770 30.670 5.670 -0.057     
2nd line year 6-12     Disutil Net Undisc Disc %Total 
Lira 1.2 30.019 0.577 30.596 5.596 -0.056 0.007 0.046 0.035 10% 
Lira 1.8 29.817 0.577 30.394 5.394 -0.054 0.009 0.060 0.045 11% 
Rosiglitazone 30.670 0.577 31.247 6.247 -0.062     
Total year 1-12      Net Undisc Disc %Total 
Lira 1.2      0.007 0.078 0.065 20% 
Lira 1.8      0.009 0.102 0.085 21% 
Glargine From  To Excess Annual Annual Period Period  
1st line year 1-5 BMI ΔBMI BMI BMI25+ Disutil Net Undisc Disc %Total 
Lira 1.8 30.500 -0.644 29.856 4.856 -0.049 0.012 0.061 0.057 24% 
Glargine 30.500 0.577 31.077 6.077 -0.061     
2nd line year 6-12     Disutil Net Undisc Disc %Total 
Lira 1.8 29.856 0.577 30.433 5.433 -0.054 0.006 0.045 0.034 14% 
Glargine 31.077 0.000 31.077 6.077 -0.061     
Total year 1-12      Net Undisc Disc %Total 
Lira 1.8      0.006 0.106 0.091 38% 
Exenatide From  To Excess Annual Annual Period Period  
1st line year 1-5 BMI ΔBMI BMI BMI25+ Disutil Net Undisc Disc %Total 
Lira 1.8 32.950 -1.145 31.805 6.805 -0.068 0.001 0.006 0.006 4% 
Exenatide 32.950 -1.015 31.935 6.935 -0.069     
2nd line year 6-12     Disutil Net Undisc Disc %Total 
Lira 1.8 31.805 0.577 32.382 7.382 -0.074 0.001 0.009 0.007 4% 
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Exenatide 31.935 0.577 32.512 7.512 -0.075     
Total year 1-12      Net Undisc Disc %Total 
Lira 1.8      0.001 0.016 0.013 8% 
Sitagliptin From  To Excess Annual Annual Period Period  
1st line year 1-5 BMI ΔBMI BMI BMI25+ Disutil Net Undisc Disc %Total 
Lira 1.2 32.800 -1.000 31.800 6.800 -0.068 0.007 0.033 0.031 16% 
Lira 1.8 32.800 -1.180 31.620 6.620 -0.066 0.008 0.042 0.039 13% 
Sitagliptin 32.800 -0.340 32.460 7.460 -0.075     
2nd line year 6-12     Disutil Net Undisc Disc %Total 
Lira 1.2 31.800 0.577 32.377 7.377 -0.074 0.007 0.046 0.035 19% 
Lira 1.8 31.620 0.577 32.197 7.197 -0.072 0.008 0.059 0.045 15% 
Sitagliptin 32.460 0.577 33.037 8.037 -0.080     
Total year 1-12      Net Undisc Disc %Total 
Lira 1.2      0.007 0.079 0.066 35% 
Lira 1.8      0.008 0.101 0.084 27% 
 
Within the above, the percentage total is the percentage of the base case total utility gain from 
liraglutide that would be attributable to the direct utility effects of weight. The above has been 
confirmed by the manufacturer as the correct interpretation of the application of the direct utility 
effects of weight changes within the modelling. Unfortunately, within the above the utility gains relate 
to a patient of 12 years survival, the approximate average discounted survival reported within the 
submission.  
 
Undiscounted survival was not reported within the submission, but the average  appears to be around 
16 years. Applying the weight changes to an average survival of 16 years using the same methodology 
as above results in the following average gains from the direct utility impacts of weight changes as a 
percentage of the total QALY gain anticipated from liraglutide over the comparator treatment reported 
for the basecases. 
 
Table 58 Weight change utilities over 16 years 
 1860 LEAD5 LEAD6 LEAD1 LEAD2 
 1.2mg 1.8mg 1.8mg 1.8mg 1.2mg 1.8mg 1.2mg 1.8mg 
1st line year 1-5 *** *** 24% 4% 9% 10% 24% 25% 
2nd line year 6-16 *** *** 21% 6% 15% 17% 41% 42% 
Total year 1-16 *** *** 45% 10% 25% 27% 65% 67% 
 
**********************************************************************************
**********************************************************************************
**********************************************************************************
************************************ 
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Appendix 8 UKPDS 65 Costs 
Costs of events in UKPDS 65 consisted of an inpatient cost and an outpatient cost associated with 
events. The costs cross checked with those of UKPDS 65 as outlined below. 
 
Table 59 UKPDS costs 
Costs drawn from UKPDS IP OP Total Submission 
Fatal MI £1,152 £0 £1,152 £1,152 
MI, year 1 £4,070 £315 £4,385 £4,385 
MI, year 1+ £464 £258 £722 £722 
Angina, year 1 £1,959 £315 £2,274 £2,274 
Angina, year 1+ £493 £258 £751 £751 
Congestive heart failure, year 1 £2,221 £315 £2,536 £2,536 
Congestive heart failure, year 1+ £631 £258 £889 £889 
Stroke, fatal £3,383 £0 £3,383 £3,383 
Stroke, year 1 £2,367 £315 £2,682 £2,682 
Stroke, year 1+ £249 £258 £507 £507 
Severe vision loss/blindness, year 1 £872 £0 £872 £872 
Severe vision loss/blindness, year 1+ £281 £0 £281 £281 
Cataract extraction £1,553 £0 £1,553 £1,553 
Cataract annual follow-up £105 £0 £105 £105 
Amputation, year 1 £8,459 £315 £8,774 £8,774 
Amputation, year 1+ £300 £258 £558 £558 
 
The outpatient costs within UKPDS 65 by first diabetes related complication are: 
 
Table 60 UKPDS outpatient costs 
 OP 
No complications £159 
Macrovascular year 1 £315 
Microvascular year 1 £273 
Macrovascular year 1+ £258 
Microvascular year 1+ £204 
 
There is likely to be a degree of double counting of outpatient costs, given that these are associated 
with the first diabetes related complication. Patients with a previous macrovascular event such as MI 
may have another subsequently, such as stroke. The costs as applied by the manufacturer would apply 
two sets of outpatient costs when it would appear that within UKPDS 65 only one set of outpatient 
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costs should be applied to this. But within the CORE model structure there is no simple means of 
adjusting costs for this and the approach adopted does not seem unreasonable. 
 
It could be argued that vision loss should have attracted the microvascular OP costs. 
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